ORIGINAL RESEARCH

UDC: 616.127-005.4-073.756.8

DOI: 10.20969/VSKM.2024.17(2).7-13

UDC 615.456.1

DOI: 10.20969/VSKM.2024.17(2).14-22

REFERENCES

 

 

UDC 303.621.35:616.248

DOI: 10.20969/VSKM.2024.17(2).23-33

REFERENCES 

1. Global Strategy for Asthma Management and Prevention.. The GINA reports. 2019. URL: http://www.ginasthma.org

2. Chuchalin AG, Khaltaev N, Аntonov NS, et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J Chron Obstruct Pulmon Dis. 2014; 12 (9): 963–974. DOI: 10.2147/COPD.S67283

3. Чучалин А.Г., Абелевич М.М., Архипов В.В. [и др.]. Национальная программа «Бронхиальная астма у детей. Стратегия лечения и профилактика». IV издание. Москва. –2012. [Chuchalin AG, Abelevich MM, Arkhipov VV, et al. Nacional’naya programma «Bronhial’naya astma u detej; Strategiya lecheniya i profilaktika» 4 izdaniye [National program “Bronchial asthma in children; Treatment  strategy and prevention” 4th edition]. Moskva [Moscow]. 2012. (In Russ.)]. Режим доступа [URL]: https://elibrary.ru/item.asp?id=23562294

4. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2023. URL: www.ginasthma.org
5. Бонцевич Р.А., Михно А.В., Щуровская К.В. [и др.]. Оценка уровня базовых знаний по бронхиальной астме у студентов старших курсов – финальные результаты исследования ASSA // Фарматека. – 2019. – Т. 26, No 5. – С.102–109. [Bontsevich RA, Mikhno AV, Shchurovskaya KV, et al. Ocenka urovnya bazovyh znanij po bronhial’noj astme u studentov starshih kursov – final’nye rezul’taty issledovaniya ASSA [Assessment of the basic knowledge about the bronchial asthma among senior students – the finalresultsoftheASSAstudy]. Farmateka[Pharmateka]. 2019; 26 (5): 102–109. (In Russ.)]. DOI: 10.18565/ pharmateca.2019.5.102–109

6. Бонцевич Р.А., Землянская О.И., Михно А.В. [и др.]. Итоговые результаты исследования ASSA–II: знания врачей терапевтического профиля по бронхиальной астме // Научные результаты биомедицинских исследований. – 2020. – Т.6, No3. – С.367–383. [Bontsevich RA, Zemlyanskaya OI, Mikhno AV, et al. Itogovye rezul’taty issledovaniya ASSA–II: znaniya vrachej terapevticheskogo profilya po bronhial’noj astme [Final results of ASSA–II study: knowledge of doctors therapeutic profile for bronchial asthma]. Nauchnye rezul’taty biomedicinskih issledovanij [Scientific results of biomedical research].
2020; 6 (3): 367–383. (In Russ.)]. DOI: 10.18413/2658–6533–2020–6–3–0–7

7. Российское респираторное общество. Бронхиальная астма. Клинические рекомендации. 2019. [Rossijskoe respiratornoe obshchestvo [Russian Respiratory Society]. Bronhial’naya astma: Klinicheskie rekomendacii [Bronchial asthma: Clinical guidelines]. 2019. (In Russ.)]. Режим доступа [URL]: https://spulmo.ru/upload/kr_ bronhastma_2019.pdf

8. Авдеев С.Н., Ненашева Н.М., Жуденков К.В. [и др.]. Распространенность, заболеваемость, фенотипы и другие характеристики тяжелой бронхиальной астмы в Российской Федерации // Пульмонология. – 2018. – Т.28, No3. – С.341–358. [Avdeev SN, Nenasheva NM, Zhudenkov KV, et al. Rasprostranennost’, zabolevaemost’, fenotipy i drugie harakteristiki tyazheloj bronhial’noj astmy v Rossijskoj Federacii [Prevalence, morbidity, phenotypes and other characteristics of severe bronchial asthma in Russian Federation]. Pul’monologiya [Pulmonology]. 2018; 28 (3): 341–358 (In Russ.)]. DOI: 10.18093/0869– 0189–2018–28–3–341–358

9. Чучалин А.Г. ред. Респираторная медицина: руководство: в 3–х томах // Рос. респираторное о–во. – М.: Литтерра, 2017. – 640 с., 544 с., 464 с. [Chuchalin AG ed. Respiratornaya medicina: rukovodstvo: v 3–h tomah [Respiratory medicine: manual: in 3 volumes]. LitTerra [LitTerra]. 2017; 640 p., 544 p., 464p. (In Russ.)].

10. Белевский А.С. Современная терапия бронхиальной астмы, шаг вперед // Астма и аллергия. – 2013. – No. 3. – С.16–19. [Belevsky AS. Sovremennaya terapiya bronhial’noj astmy, shag vpered [Modern therapy of bronchial asthma, a step forward]. Astma i allergiya [Asthma and allergy]. 2013; (3): 16–19. (In Russ.)]. URL: https://elibrary.ru/item.asp?id=25916565

11. Horak F, Doberer D, Eber E, Horak E, et al. Diagnosis and management of asthma – Statement on the 2015 GINA Guidelines. Wien Klin Wochenschr. 2016; 128 (15): 541–554. DOI:10.1007/s00508–016–1019–4

12. Levy ML, Bacharier LB, Bateman E, et al. Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update. Prim Care Respir Med. 2023; 33 (7): 13 p. URL: https://doi.org/10.1038/ s41533–023–00330–1

13. Reddel HK, Bateman ED, Schatz M, et al. A Practical Guide to Implementing SMART in Asthma Management. J Allergy Clin Immunol Pract. 2022; 10 (1S): S31–S38. DOI: 10.1016/j.jaip.2021.10.011

14. Ichinose M, Sugiura H, Nagase H, et al. Japanese guidelines for adult asthma 2017. Allergol Int. 2017; 66 (2): 163– 189. DOI: 10.1016/j.alit.2016.12.005

15. Fitzpatrick AM, Moore WC. Severe Asthma Phenotypes – How Should They Guide Evaluation and Treatment? J Allergy Clin Immunol Pract. 2017; 5 (4): 901–908. DOI: 10.1016/j. jaip.2017.05.015

16. The Global Asthma Report, 2022. Global Asthma Network. 2022. URL: http://www.globalasthmanetwork.org

 

UDC 543.544.943.3

DOI: 10.20969/VSKM.2024.17(2).34-39

REFERENCES

 

 

UDC 616.24–008.46

DOI: 10.20969/VSKM.2024.17(2).40-44

REFERENCES

 

 

UDC: 616.3-008.13

DOI: 10.20969/VSKM.2024.17(2).45-51

REFERENCES

1. Romijnders K, van Osch L, de Vries H, Talhout R. Perceptions and reasons regarding e–cigarette use among users and non–users: a narrative literature review. Int J Environ Res Public Health. 2018; 15(6):1190. DOI:10.3390/ijerph15061190

 

UDC: 616.24-002-022.6-06:616.988:616.153.96

DOI: 10.20969/VSKM.2024.17(2).52-57

REFERENCES

 

 UDC 616.24-008.46:613

DOI: 10.20969/VSKM.2024.17(2).58-63

REFERENCES

1. Чучалин АГ. Российское респираторное общество. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких // Пульмонология. – 2014. – № 3. – C.15–54. [Chuchalin AG. Rossijskoe respiratornoe obshhestvo. Federal`ny`e klinicheskie rekomendacii po diagnostike i lecheniyu xronicheskoj obstruktivnoj bolezni legkix [The Russian Respiratory Society. Federal clinical guidelines for the diagnosis and treatment of chronic obstructive pulmonary disease]. Pul`monologiya [Pulmonology]. 2014; 3: 15–54. (In Russ.)].

2. Eisner MD, Anthonisen N, Coultas D, et al. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010; 182: 693–718. (http://www.goldcopd.com). DOI: 10.1164/rccm.200811–1757ST

3. Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2018. https://goldcopd.org/wp–content/uploads/2017/11/GOLD–2018–v6.0–FINAL–revised–20–Nov_WMS.pdf

4. Global strategy for the diagnosis, management, and prevention of Chronic Obstructive Pulmonary Disease. 2015. https://www.atsjournals.org/doi/pdf/10.1164/ajrccm.163.5.2101039

5. Российское респираторное общество. Федеральные клинические рекомендации «Хроническая обструктивная болезнь легких». – Москва: Министерство Здравоохранения Российской Федерации, 2018. – 76 с. [Rossiyskoye respiratornoye obshchestvo [Russian Respiratory Society]. Federal’nyye klinicheskiye rekomendatsii «Khronicheskaya obstruktivnaya bolezn’ legkikh» [Federal clinical guidelines “Chronic obstructive pulmonary disease”]. Moskva: Ministerstvo Zdravookhraneniya Rossiyskoy Federatsii [Moscow: Ministry of Health of the Russian Federation]. 2018; 76 p. (In Russ.)]. https://spulmo.ru/upload/federal_klinicheskie_rekomendaciy_hobl.pdf?ysclid=ltg98sbfh7484687721

6. Lamprecht B, McBurnie MA, Vollmer WM, et al. BOLD Collaborative Research Group: COPD in never smokers: results from the population–based burden of obstructive lung disease study. Chest. 2011; 139: 752–763. (http://www.goldcopd.com). DOI: 10.1378/chest.10–1253.

7. Агеева О.Н., Юшманова Е.В., Ким А.О. Исследования наличия связи курения и ХОБЛ // Инновации. Наука. Образование. – 2020. – №19. – C.710–715. [Ageeva ON, Yushmanova EV, Kim AO. Issledovaniya nalichiya svyazi kureniya i XOBL [Studies on the link between smoking and COPD]. Innovacii; Nauka; Obrazovanie [Innovation; Science; Education]. 2020; 19: 710–715. (In Russ.)].

8. Визель А.А., Визель И.Ю. Хроническая обструктивная болезнь легких — от истоков к современности (исторический̆ обзор литературы) // Туберкулез и болезни легких. – 2019. – Т. 97, №2. – C.42–49. [Vizel AA, Vizel IYu. Xronicheskaya obstruktivnaya bolezn legkix — ot istokov k sovremennosti (istoricheskiĭ obzor literatury) [Chronic obstructive pulmonary disease — from the origins to the present (historical review of literature)]. Tuberkulez i bolezni legkix [Tuberculosis and lung diseases]. 2019; 97 (2): 42–49. (In Russ.)]. DOI 10.21292/2075–1230–2019–97–2–42–49

9. Максимов Д.М., Глуховская С.В., Андриянова О.В. Региональная программа «Медицина без табака» – предварительные результаты // Здравоохранение Российской Федерации. – 2015, №3. – C.43–46. [Maksimov DM, Gluhovskaya SV, Andriyanova OV. Regional`naya programma «Medicina bez tabaka» – predvaritel`ny`e rezul`taty [Regional program «Tobacco free medicine» — preliminary results]. Zdravooxranenie Rossijskoj Federacii. [Healthcare of the Russian Federation]. 2015; 3: 43–46. (In Russ.)].

10. Остроумова О.Д., Кочетков А.И., Полякова О.А. [и др.]. Влияние курения на заболевания терапевтического профиля. Управление рисками. Учебное пособие. – Москва: ФГБОУ ДПО РМАНПО Минздрава России, 2022. – 123 c. [Ostroumova OD, Kochetkov AI, Polyakova OA, et al. Vliyanie kureniya na zabolevaniya terapevticheskogo profi lya; Upravlenie riskami; Uchebnoe posobie [The effect of smoking on therapeutic diseases; Risk management; A study guide]. Moskva: FGBOU DPO RMANPO Minzdrava Rossii [Moscow: Federal State Budgetary Educational Institution of the Russian Ministry of Health]. 2022; 123 p. (In Russ.)].

11. WHO Regional Offi ce for Europe. European Tobacco Control Status Report 2013: Death from tobacco. Copenhagen: WHO Regional Offi ce for Europe. 2013; 50 p. https://www.drugsandalcohol.ie/21023/1/European–Tobacco–Control–Status–Report–2013–Eng.pdf

12. Илькович М.М., Кузубова Н.А., Киселева Е.А. Борьба с табакокурением, как основа профилактики хронической обструктивной болезни легких // Пульмонология. – 2010. – № 2. – C.37–39. [Ilkovich MM, Kuzubova NA, Kiseleva EA. Bor`ba s tabakokureniem, kak osnova profi laktiki xronicheskoj obstru ktivnoj bolezni legkix [Tobacco control as a basis for the prevention of chronic obstructive pulmonary disease]. Pul`monologiya [Pulmonology]. 2010; 2: 37–39. (In Russ.)].

13. Raad D, Gaddam S, Schunemann HJ, et al. Effects of water–pipe smoking on lung function: a systematic review and meta–analysis. Chest. 2011; 139: 764–774. 

14. World Health Organization. Tobacco fact sheet № 339. Geneva: World Health Organization. 2013. http://www.who.int/mediacentre/factsheets/fs339/en/

15. Антонов В.Н., Игнатова Г.Л., Родионова О.В. [и др.]. Табакокурение и функциональное состояние респираторной системы у больных с хронической обструктивной болезнью легких // Сибирское медицинское обозрение. – 2014. – № 6, вып.90. – С.75–78. [Antonov VN, Ignatova GL, Rodionova OV, et al. Tabakokurenie i funkcional`noe sostoyanie respiratornoj sistemy` u bol`ny`x s xronicheskoj obstruktivnoj bolezn`yu legkix [Smoking and the functional state of the respiratory system in patients with chronic obstructive pulmonary disease]. Sibirskoe medicinskoe obozrenie [Siberian Medical Review]. 2014; 6 (90): 75–78. (In Russ.)].

16. Ануварбекова А.А., Уланбекова Т.У. Никотиновая зависимость и факторы, мотивирующие и поддерживающие ее // Международный журнал прикладных и фундаментальных исследований. – 2017. – №12, вып.2. – С.257–260. [Anuvarbekova AA, Ulanbekova TU. Nikotinovaya zavisimost` i faktory`, motiviruyushhie i podderzhivayushhie ee [Nicotine addiction and factors motivating and supporting it]. Mezhdunarodny`j zhurnal prikladny`x i fundamental`ny`x issledovanij [International Journal of Applied and Fundamental Research]. 2017; 12(2): 257–260. (InRuss.)].

17. Амиров Н.Б., Андреева Т.И. Табачная эпидемия: фармакологические возможности борьбы // Вестник современной клинической медицины. – 2011. – T.4, вып.3. – С.28–33. [Amirov NB, Andreeva TI. Tabachnaya epidemiya: farmakologicheskie vozmozhnosti bor’by [Tobac co epidemic: pharmacological possibilities ofcontrol]. Vestnik sovremennoj klinicheskoj mediciny [Bulletin of contemporary clinical medicine]. 2011; 4(3): 28–33 (InRuss.)].

18. Сахарова Г.М., Антонов Н.С. Табакокурение и репродуктивная функция женщин // Российский медицинский журнал «Мать и Дитя». – 2013. – № 1. – C.12–20. [Saharova GM, Antonov NS. Tabakokurenie i reproduktivnaya funkciya zhenshhin. [Tobacco smoking and the reproductive function of women]. Rossiyskiy meditsinskiy zhurnal «Mat’ i Ditya» [Russian medical journal “Mother and Child”]. 2013; 1: 12–20. (In Russ.)].

19. Дикке Г.Б. Курение табака среди женщин и стратегия успешного отказа от табакокурения во время беременности // Фарматека. – 2014. – № 5. – С.76–79. [Dikke GB.Kurenie tabaka sredi zhenshhin i strategiya uspeshnogo otkaza ot tabakokureniya vo vremya beremennosti [Tobacco smoking among women and the strategy to successfully quit smoking during pregnancy]. Farmateka [Pharmateca]. 2014; 5: 76–79. (In Russ.)].

20. Цветкова О.А., Мустафина М.Х. Хроническая обструктивная болезнь легких у женщин // Пульмонология. – 2010. – №1.– С.111–118. [Cvetkova OA, Mustafi na MH. Xronicheskaya obstruktivnaya bolezn` legkix u zhenshhin [Chronic obstructive pulmonary disease in women]. Pul`monologiya [Pulmonology]. 2010; 1: 111–118. (In Russ.)]. DOI:10.18093/0869–0189–2010–1–111–118

21. Лотков В.С., Дзюбайло А.В. Прогнозирование вероятности развития ХОБЛ в зависимости от стажа курения женщин фертильного возраста // Вестник современной клинической медицины. – 2023. – Т.16, вып. 2. – С.34–38. [Lotkov VS, Dzyubailo AV. Prognozirovanie veroyatnosti razvitiya HOBL v zavisimosti ot stazha kureniya zhenshhin fertil`nogo vozrasta [Predicting the likelihood of COPD development depending on the smoking experience of women of fertile age]. Vestnik sovremennoj klinicheskoj mediciny [Bulletin of contemporary clinical medicine]. 2023; 16 (2): 34–38. (In Russ.)]. DOI: 10.20969/VSKM.2023.16(2).34–38

22. Дзюбайло АВ, Лотков ВС. Никотиновая зависимость и гормональный дисбаланс у беременных курильщиц с разной степенью тяжести ХОБЛ // Вестник современной клинической медицины. – 2023. – Т.16., вып.2. – С.18–22. [Dzyubailo AV, Lotkov VS. Nikotinovaya zavisimost` i gormonal`ny`j disbalans u beremenny`x kuril`shhicz s raznoj stepen`yu tyazhesti НOBL [Nicotine dependence and hormonal imbalance in pregnant smokers with varying degrees of COPD severity]. Vestnik sovremennoj klinicheskoj mediciny [Bulletin of contemporary сlinical medicine]. 2023; 16 (2): 18–22. (In Russ.)]. DOI:10.20969/VSKM.2023.16(2).18–22

 

UDC 616.127-005.8

DOI: 10.20969/VSKM.2024.17(2).64-70

REFERENCES

 

UDC: 618.3-06

DOI: 10.20969/VSKM.2024.17(2).71-78

REFERENCES 

1. Беженарь В.Ф., Зазерская И.Е., Беттихер О.А. [и др.]. Спорные вопросы акушерской тактики при ве-дении беременности и родоразрешении пациенток с новой коронавирусной инфекцией COVID–19 //Акушерство и гинекология. – 2020. – No 5. – С.13–21. [Bezhenar VF, Zazerskaya IE, Bettikher OA, еt al. Sporny`e voprosy` akusherskoj taktiki pri vedenii beremennosti i rodorazreshenii pacientok s novoj koronavirusnoj infekciej COVID–19 [Controversial issues in obstetric management of women with novel coronavirus disease COVID–19 during pregnancy and childbirth]. Akusherstvo i ginekologiya [Obstetrics and Gynecology]. 2020; 5: 13–21. (In Russ.)]. DOI: 10.18565/aig.2020.5.13–21

2. Белокриницкая Т.Е., Артымук Н.В., Филиппов О.С.,Фролова Н.И. Материнские и перинатальные исходы в условиях пандемии новой коронавирусной инфекцииCOVID–19 в Дальневосточном и Сибирском федераль-ных округах // Проблемы репродукции. – 2021. – Т. 27, вып. 2. – С.130–136. [Belokrinitskaya TE, Artymuk NV, Filippov OS, Frolova NI. Materinskie i perinatal`ny`e isxody` v usloviyax pandemii novoj koronavirusnoj infekcii COVID–19 v Dal`nevostochnom i Sibirskom federal`ny`x okrugax [Maternal and perinatal outcomes during COVID–19 pandemia in far east and siberian federal region of Russia]. Problemy reprodukcii [Russian Journal Of Human Reproduction]. 2021; 27 (2): 130–136. (In Russ.)]. DOI: 10.17116/repro202127021130

3. Синчихин С.П., Степанян Л.В., Мамиев О.Б. Новая коронавирусная инфекция и другие респираторные вирусные заболевания у беременных: клиническая лекция // Гинекология. – 2020. – Т. 22, вып. 2. – С.6–16. [Sinchikhin S P, Stepanyan LV, Mamiev OB. Novaya koronavirusnaya infekciya i drugie respiratorny`e virusny`e zabolevaniya u beremenny`x: klinicheskaya lekciya [New coronoviral infection and other respiratory–viral diseases in pregnant women: clinical lecture]. Ginekologiya [Gynecology]. 2020; 22 (2): 6–16. (In Russ.)]. DOI: 10.26442/20795696.2020.2.200129

4. Романовская А.В., Давыдов А.И., Хворостухина Н.Ф. [и др.]. Фетоплацентарная недостаточность и сроки ее коррекции у беременных с гриппом // Во-просы гинекологии, акушерства и перинатологии. – 2018. – Т. 17, вып. 3. – С.41–44. [Romanovskaya AV, Davydov AI, Khvorostukhina NF, еt al. Fetoplacentarnaya nedostatochnost` i sroki ee korrekcii u beremenny`x s grippom [Fetoplacental insufficiency and terms of its management in pregnant women with influenza]. Voprosy Ginekologii, Akusherstva i Perinatologii [Gynecology, Obstetrics and Perinatology]. 2018; 17 (3): 41–44. (In Russ.)]. DOI: 10.20953/1726–1678–2018–3–41–44

5. Zafari M, Rad MTS, Mohseni F. Coronavirus Disease 2019 (COVID–19) and Pregnancy: A Narrative Review. Curr Pediatr Rev. 2022; 18 (2): 97–102. DOI: 10.2174/157339 6317666210920152541

6. Шевелева Д.И., Романовская А.В., Хворостухина Н.Ф. Особенности течения вирусной инфекции COVID–19 при беременности // Практическая медицина. – 2020. – Т. 18, вып. 6. – С.20–23. [Sheveleva DI, Romanovskaya AV, Khvorostukhina NF. Osobennosti techeniya virusnoj infekcii COVID–19 pri beremennosti [Features of virus infection COVID–19 during the pregnancy]. Prakticheskaya Medicina [Practical medicine]. 2020; 18 (6): 20–23. (In Russ.)]. DOI: 10.32000/2072–1757–2020–6–20–23

7. Шевлюкова Т.П., Жусупова Ж.К., Соловьева Е.Н. Ассоциативное влияние новой коронавирусной инфекции SARS–COV–2, перенесенной в период беременности, на формирование неврологических нарушений новорожденных: клинический случай // Пермский медицинский журнал. – 2021. – Т. 38, вып. 5. – С.165–172. [Shevlyukova TP, Zhusupova ZhK, Solovyeva EN. Associativnoe vliyanie novoj koronavirusnoj infekcii SARS–COV–2, perenesennoj v period beremennosti, na formirovanie nevrologicheskix narushenij novorozhdenny`x: klinicheskij sluchaj [Associative influence of new coronavirus infection SARS– COV–2 during pregnancy on formation of neurological disorders in newborns: clinical case]. Permskij Medicinskij Zhurnal [Perm Medical Journal]. 2021; 38 (5): 165–172. (In Russ.)]. DOI: 10.17816/pmj385165–172

8. Логинова И.А., Устинович А.А., Альферович Е.Н. [и др.]. Некоторые аспекты клинико–лабораторных показателей у новорожденных от матерей с коронавирусной инфекцией, вызванной SARS–COV–2 (COVID–19), инфицированных в различные сроки перинатального периода // Неотложная кардиология и кардиоваскулярные риски. – 2021. – Т. 5, вып. 1. – С.1202–1209. [Loginova IA, Ustinovich AA, Alferovich EN, еt al. Nekotory`e aspekty` kliniko–laboratorny`x pokazatelej u novorozhdenny`x ot materej s koronavirusnoj infekciej, vy`zvannoj SARS– COV–2 (COVID–19), inficirovanny`x v razlichny`e sroki perinatal`nogo perioda [Some aspects of clinical and laboratory parameters in newborns from mothers with coronavirus infection SARS–COV–2 (COVID–19), infected at different times of perinatal period]. Neotlozhnaya Kardiologiya i Kardiovaskulyarnye Riski [Emergency Cardiology and Cardiovascular Risks]. 2021; 5 (1): 1202– 1209. (In Russ.)]. DOI: 10.51922/2616633X.2021.5.2.1202

9. Wang X, Zhou Z, Zhang J, еt al. A Case of 2019 Novel Coronavirus in a Pregnant Woman With Preterm Delivery. Clin Infect Dis. 2020; 71 (15): 844–846. DOI: 10.1093/ cid/ciaa200

10. Кравченко Е.Н., Демченко С.Г., Шиковец В.В. [и др.]. Опыт применения препарата метрогил плюс у беременных с вульвовагинальным кандидозом и новой коронавирусной инфекцией COVID–19 // Доктор. Ру. – 2021. – Т. 20, вып. 1. – С.68–72. [Kravchenko EN, Demchenko SG, Shikovets VV, еt al. Opy`t primeneniya preparata metrogil plyus u beremenny`x s vul`vovaginal`ny`m kandidozom i novoj koronavirusnoj infekciej COVID–19 [Experience with using metrogyl plus in pregnant women with vulvovaginal candidiasis and the new coronavirus infection COVID–19]. Doktor. Ru [Doctor.Ru]. 2021; 20 (1): 68–72. (In Russ.)]. DOI: 10.31550/1727–2378–2021–20–1–68–72

11. Хворостухина Н.Ф., Степанова Н.Н., Новичков Д.А., Силкина А.А. Особенности течения пуэрперия при преждевременных родах с длительным безводным промежутком // Медицинский совет. – 2021. – No 3. – С.82–88. [Khvorostukhina NF, Stepanova NN, Novichkov DA, Silkina AA. Osobennosti techeniya pue`rperiya pri prezhdevremenny`x rodax s dlitel`ny`m bezvodny`m promezhutkom [Features of the course of puerperium in preterm birth with a long anhydrous interval]. Medicinskij Sovet [Medical Council]. 2021; 3: 82–88. (In Russ.)]. DOI: 10.21518/2079–701X–2021–3–82–88

12. Stepanova NN, Khvorostukhina NF, Suvorova GS. Obstetric and perinatal outcomes of preterm labor with a long waterless interval. Practice Oriented Science: UAE – RUSSIA – INDIA: Proceedings of the International University Scientific Forum. UAE, 08 November 2022. UAE: Infinity. 2022; 33–42.

13. Saadaoui M, Kumar M, Al Khodor S. COVID–19 Infection during pregnancy: risk of vertical transmission, fetal, and neonatal outcomes. J Pers Med. 2021; 11 (6): 483. DOI: 10.3390/jpm11060483

14. Романовская А.В., Малеев В.В., Хворостухина Н.Ф. Влияние гриппа на течение беременности, развитие плода и состояние здоровья новорожденного // Вопросы гинекологии, акушерства и перинатологии. – 2014. – Т. 13, вып. 2. – С.49–53. [Romanovskaya AV, Maleyev VV, Khvorostukhina NF. Vliyanie grippa na techenie beremennosti, razvitie ploda i sostoyanie zdorov`ya novorozhdennogo [Effect of influenza in the course of pregnancy, development of the foetus and the state of health of a newborn child]. Voprosy Ginekologii, Akusherstva i Perinatologii [Gynecology, Obstetrics and Perinatology]. 2014; 13 (2): 49–53. (In Russ.)]. EDN: https://elibrary.ru/skjcel

15. Хабибрахманова Л.Х., Фирсова Е.В., Садардинова Р.Р. Влияние COVID–19 на течение беременности в первом триместре // Здравоохранение Чувашии. – 2021. – No 2. – С.92–99. [Khabibrakhmanova LKh, Firsova EV, Sadardinova RR. Vliyanie COVID–19 na techenie beremennosti v pervom trimestre [The effect of COVID–19 on the course of pregnancy in the first trimester]. Zdravoohranenie Chuvashii [Chuvashia Healthcare]. 2021; 2: 92–99. (In Russ.)]. DOI: 10.25589/ GIDUV.2021.96.94.008

 

 

UDC 616-036.17

DOI: 10.20969/VSKM.2024.17(2).79-84

REFERENCES

1. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010; 69 (10): 1809–1815. DOI: 10.1136/ard.2009.114264

 

UDC: 616:612.017.1

DOI: 10.20969/VSKM.2024.17(2).85-90

 BIOLOGIC MARKERS OF FIBROGENESIS IN PULMONARY SARCOIDOSIS PATIENTS

REFERENCES

1. Айсанов З. Р., Амиров Н. Б., Баранова О. П., [и др.]. Саркоидоз: монография / научный редактор А. А. Визель; Российское респираторное общество. – Москва; Атмосфера, 2010. – 416 с. [Aysanov ZR, Amirov NB, Baranova OP, et al. Vizel AA ed. Sarkoidoz: Monografiya [Sarcoidosis: monograph]. Moskva: Izdatelskiy holding «Atmosfera» [Moscow: Publishing Holding «Atmosphere»]. 2010; 416 р. (in Russ.)].

2. Crouser ED, Maier LA, Wilson KC, et al. Diagnosis and detection of sarcoidosis. An offi cial American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med 2020; 201: e26–e51. DOI: 10.1164/rccm.202002-0251ST

3. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999; 160 (2): 736-755. DOI: 10.1164/ajrccm.160.2.ats4-99

4. Baughman RP, Field S, Costabel U, et al. Sarcoidosis in America. Analysis Based on Health Care Use. Ann Am Thorac Soc. 2016; 13 (8): 1244-1252. DOI: 10.1513/AnnalsATS.201511-760OC

5. Ungprasert P, Carmona EM, Utz JP, Ryu JH, et al. Epidemiology of Sarcoidosis 1946-2013: A Population-Based Study. Mayo Clin Proc. 2016; 91 (2): 183-188. DOI: 10.1016/j.mayocp.2015.10.024

6. Шмелев Е.И. Саркоидоз // Практическая пульмонология. – 2004. – №. 2. – С.3-10. [Shmelev EI. Sarkoidoz [Sarcoidosis]. Prakticheskaya pul’monologiya [Practical pulmonology]. 2004; 2: 3-10. (in Russ.)].

7. Bonham CA, Strek ME, Patterson KC. From granuloma to fi brosis: sarcoidosis associated pulmonary fi brosis. Curr Opin Pulm Med. 2016; 22 (5): 484-491. DOI:10.1097/MCP.0000000000000301

8. Spagnolo P, Rossi G, Trisolini R. et al. Pulmonary sarcoidosis. Lancet Respir Med. 2018; 6 (5): 389-402. DOI: 10.1016/S2213-2600(18)30064-X

9. Arkema EV, Grunewald J, Kullberg S, et al. Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden. Eur Respir J. 2016; 48 (6): 1690-1699. DOI: 10.1183/13993003.00477-2016

10. Hoffmann AL, Milman N, Byg KE. Childhood sarcoidosis in Denmark 1979-1994: incidence, clinical features and laboratory results at presentation in 48 children. Acta Paediatr. 2004; 93 (1): 30-36. DOI: 10.1111/j.1651-2227.2004.tb00670.x

11. Чучалин А.Г., Авдеев С.Н., Айсанов З.Р., [и др.]. Федеральные клинические рекомендации Российского респираторного общества по диагностике и лечению саркоидоза // М-во здравоохранения Российской Федерации, Российское респираторное общество, Общероссийское педиатрическое респираторное общество, Российское научное медицинское общество терапевтов. Москва, 2019. – 47 c. [Chuchalin AG, Avdeev SN, Ajsanov Z, et al. Federal’nye klinicheskie rekomendacii Rossijskogo respiratornogo obshchestva po diagnostike i lecheniyu sarkoidoza [Russian respiratory society. Federal guidelines on diagnosis and treatment of sarcoidosis]. Moskva: Ministerstvo zdravoohraneniya Rossijskoj Federacii, Rossijskoe respiratornoe obshchestvo, Obshcherossijskoe pediatricheskoe respiratornoe obshchestvo, Rossijskoe nauchnoe medicinskoe obshchestvo terapevtov. [Moscow: Ministry of Health of the Russian Federation, Russian Respiratory Society, Russian Pediatric Respiratory Society, Russian Scientic Medical Society of Therapists]. 2019; 47 p. (in Russ)].

12. Debabrata Bandyopadhyay, Mehdi S. Mirsaeidi. Sarcoidosis-associated pulmonary fi brosis: joining the dots. European Respiratory Review. 2023; 32 (169): 230085. DOI: 10.1183/16000617.0085-2023

13. Jazwa A, Kasper L, Bak M, et al. Differential Infl ammatory MicroRNA and Cytokine Expression in Pulmonary Sarcoidosis. Arch. Immunol. Ther Exp. 2015; 63: 139–146. DOI: 10.1007/s00005-014-0315-9

14. Rajasekaran S, Rajaguru P, Sudhakar Gandhi PS. MicroRNAs as potential targets for progressive pulmonary fibrosis. Front Pharmacol. 2015; 6: 254. DOI: 10.1007/s00005-014-0315-914

15. Шепелькова Г.С., Зайцева А.С., Евстифеев В.В., [и др.]. МикроРНК как маркеры фиброзирования у пациентов с гиперчувcтвительным пневмонитом // Медицинская иммунология. [Shepelkova GS, Zaytseva AS, Evstifeev VV, et al. MikroRNK kak markery fi brozirovaniya u pacientov s giperchuvctvitel’nym pnevmonitom [MicroRNAs as fibrosis markers in patients with hypersensitivity pneumonitis]. Medicinskaya immunologiya [Medical Immunology (Russia)] (In Russ.)]. Режим доступа: https://www.mimmun.ru/mimmun/article/view/2913/1830 DOI: 10.15789/2220-7619-MAM-2913

16. Shepelkova GS, Evstifeev VV, Tarasov RV, et al. MicroRNAs as Biomarkers of Active Pulmonary TB Course. Microorganisms. 2023; 11: 626. DOI: 10.3390/microorganisms11030626

17. Kuse N, Kamio K, Azuma A, et al. Exosome-Derived microRNA-22 Ameliorates Pulmonary Fibrosis by Regulating Fibroblast-to-Myofi broblast Differentiation in Vitro and in Vivo. J Nippon Med Sch. 2020; 87 (3): 118-128. DOI: 10.1272/jnms.JNMS.2020_87-302 18. Gong L, Zhu L, Yang T. Fendrr involves in the pathogenesis of cardiac fi brosis via regulating miR-106b/SMAD3 axis. Biochem Biophys Res Commun. 2020; 524 (1): 169-177. DOI: 10.1016/j.bbrc.2020.01.062

19. Wang YC, Xie H, Zhang YC, et al. Exosomal miR-107 antagonizes profibrotic phenotypes of pericytes by targeting a pathway involving HIF-1α/Notch1/PDGFRβ/YAP1/Twist1 axis in vitro. Am J Physiol Heart Circ Physiol. 2021; 320 (2): H520-H534. DOI: 10.1152/ajpheart.00373.2020

20. Chen ML, Fan L, Huang GR, Sun ZF. Knockdown of miR-150-5p reduces hypoxia-induced autophagy and epithelial-mesenchymal transition of endometriotic cells via regulating the PDCD4/NF-κB signaling pathway. Cytokine. 2023; 162: 156086. DOI: 10.1016/j.cyto.2022.156086

21. Shang J, He Q, Chen Y, et al. miR-15a-5p suppresses infl ammation and fi brosis of peritoneal mesothelial cells induced by peritoneal dialysis via targeting VEGFA. J Cell Physiol. 2019; 234 (6): 9746-9755. DOI: 10.1002/jcp.27660

22. Wen D, Zhang H, Zhou Y, Wang J. The Molecular Mechanisms and Function of miR-15a/16 Dysregulation in Fibrotic Diseases. Int J Mol Sci. 2022; 23 (24): 16041. DOI: 10.3390/ijms232416041

 

 

REVIEWS

UDC 616.11-002

DOI: 10.20969/VSKM.2024.17(2).91-97

REFERENCES

1. Imazio M, Gaita F, LeWinterM. Evaluation and Treatment of Pericarditis: A Systematic Review. JAMA. 2015; 314 (14):1498–506. DOI:10.1001/jama.2015.12763

2. Мячикова В.Ю., Титов В.А., Моисеева О.М. [и др.]. Идиопатический рецидивирующий перикардит – смена парадигмы? // Российский кардиологический журнал. – 2019. – Т. 24, No 11. – С.155–163. [Myachikova VYu, Titov VA, Moiseeva OM, et al. Idiopaticheskij recidiviruyushhij perikardit – smena paradigmy`? [Idiopathic recurrent pericarditis – a paradigm change?] Rossiiskiy cardiologicheskiy zhurnal [Russian Journal of Cardiology]. 2019; 24(11): 155–163. (In Russ)].

3. Marchiori E, Hochhegger B, Zanetti G. Pericardial effusion. Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia, 2021; 47 (1): e20200587. DOI:10.36416/1806–3756/ e20200587

4. Косоногов А.Я., Немирова С.В., Поздышев В.И. [и др.]. Жизнеугрожающие состояния при перикардитах различной этиологии: диагностика и лечение // Медицинский альманах. – 2019. – No 2, вып. 59. – С.40–45. [Kosonogov AYa, Nemirova SV, Pozdyshev VI, et al. [Zhizneugrozhayushchie sostoyaniya pri perikarditah razlichnoj etiologii: diagnostika i lechenie [Life–threatening conditions in pericarditis of various etiology: diagnosis and treatment] Medicinskiy almanac [Medical Almanac]. 2019; 59(2): 155–163. (In Russ)].

5. StępniakD,ŻechowiczM,MoczulskaB,etal.Inflammation of Pericardial Transverse Sinus Leading to Suspicion of Takayasu Syndrome.Am J Case Rep. 2022; 23: e937196. DOI: 10.12659/AJCR.937196.PMID: 36367847

6. Гиляревский С.Р. Диагностика и лечение заболеваний перикарда: современные подходы, основанные на доказательной информации и клиническом опыте: монография, М.: МедиаСфера, 2004. – 132 с. [Gilyarevskij SR. Diagnostika i lechenie zabolevanij perikarda: sovremennye podhody, osnovannye na dokazatel’noj informacii i klinicheskom opyte. monografiya [Diagnosis and treatment of pericardial diseases: modern approaches based on evidence–based information and clinical experience: monograph]. Moskva: MediaSfera [Moscow: Mediasphere]. 2004; 132 р. (In Russ)].

7. Улюкин И.М. Перикардит в динамике ВИЧ–инфекции // Известия Российской военно–медицинской академии. – 2018. – Т. 37, No 1. – С.35–40. [Ulyukin IM. Perikardit v dinamike VICh–infekcii [Pericarditis in the dynamics of HIV infection]. Izvestiya Rossiiskoi voenno– medicinskoi academii [News of the Russian Military Medical Academy] 2018; 37(1): 35–40. (In Russ.)].

8. Triant VA. Cardiovascular disease and HIV infection. Current HIV/AIDS reports. 2013; 10 (3): 199–206. DOI:10.1007/s11904–013–0168–6

9. Филиппов П.Г., Кускова Т.К., Еремушкина Я.М. [и др.]. Изменения структуры летальных исходов ВИЧ–инфицированных в Москве по мере развития эпидемии ВИЧ–инфекции // Московская медицина. – 2019. – No 6, вып. 34. – С.101. [Filippov PG, Kuskova TK, Eremushkina YM, et al. Izmeneniya struktury letal’nyh iskhodov VICh– inficirovannyh v Moskve po mere razvitiya epidemii VICh–infekcii [Changes in the structure of fatal outcome of HIV–infected persons in Moscow as the HIV epidemic developes]. Moscow: Medicine [Moscow: Medicine]. 2019; 34(6): 101. (In Russ)].

10. Cotter BR. Epidemiology of HIV cardiac disease. Progress in cardiovascular diseases. 2003; 45 (4): 319–326. DOI:10.1053/pcad.2003.5

11. Chaves AA, Mihm MJ, Basuray A, Baliga R, et al. HIV/ AIDS–related cardiovascular disease. Cardiovascular toxicology. 2004; 4 (3): 229–242. DOI:10.1385/ct:4:3:229

12. Болдузева С.А., Чурина М.В., Малаева Е.Г. [и др.]. Туберкулезный перикардит у пациента с ВИЧ–инфекцией // Медицинские новости. – 2022. – No 9, вып. 36. – С.33–35. [Bolduzeva SA, Churina MV, Malaeva EG, et al. Tuberkuleznyj perikardit u pacienta s VICh–infekciej [Tuberculous pericarditis in a patient with HIV infection]. Medicinskie novosti [Medical news] 2022; 336(9): 33–35. (In Russ)].

13. Syed FF, Sani MU. Recent advances in HIV–associated cardiovascular diseases in Africa. Heart. 2013; 99 (16): 1146–53.

14. Ntsekhe M, Mayosi BM. Cardiac manifestations of HIV infection: an African perspective. Nat. Clin. Pract. Cardiovasc. Med. 2009; 6 (2): 120–7.

15. So–Armah K., Benjamin LA., Bloomfield GS., Feinstein MJ., Hsue P, et al. HIV and cardiovascular disease. The lancet; HIV. 2020; 7 (4): e279–e293. DOI: 10.1016/ S2352–3018(20)30036–9

16. Мордык А.В., Калинина И.Ю., Котов И.И. [и др.]. Случай туберкулезного перикардита на фоне ВИЧ–инфекции и COVID–19 // Туберкулез и болезни легких. – 2022. – Т. 100, вып. 3. – С.18–22. [Mordyk AV, Kalinina IU, Kotov II, еt al. Sluchaj tuberkuleznogo perikardita na fone VICh– infekcii i COVID–19 [A case of tuberculous pericarditis due to HIV infection and COVID–19]. Tuberkulez i bolezni legkih [Tuberculosis and lung diseases]. 2022; 100 (3):18–22. (In Russ)]. DOI: 10.21292/2075–1230– 2022–100–3–18–22

17. Вдоушкина Е.С., Бородулина Е.А., Калинкин А.В. [и др.]. Туберкулез у больных ВИЧ–инфекцией в регионе с высоким распространением ВИЧ // Туберкулез и болезни легких. – 2018. –Т. 96, вып. 12. – С.64–65. [Vdoushkina ES, Borodulina EA, Kalinkin AV, et al. Tuberkulez u bol’nyh VICh–infekciej v regione s vysokim rasprostraneniem VICh [Tuberculosis in patients with HIV Infection IN a region with high prevalence of HIV]. Tubercules i bolesni lyogkih [Tuberculosis and lung diseases]. 2018; 96(12): 64–65. (In Russ)].

18. Бородулина Е., Вдоушкина Е., Инькова А. Туберкулез легких у больных ВИЧ–инфекцией // Врач. – 2020. – Т. 31, No 1. – С.37–43. [Borodulina E, Vdoushkina E, In’kova A. Tuberkulez legkih u bol’nyh VICh–infekciej [Tuberculosis of the lungs in patients with HIV infection]. Vrach [Doctor]. 2020; 31(1): 37–43. (In Russ)].

19. Zagdyn ZM, Nechaeva OB, Sterlikov SA, et al. HIV and HIV/TB coinfection: cluster distribution of regions in the northwestern federal district of Russia. HIV Infection and Immunosuppressive Disorders. 2022; 14 (3): 77–85.

20. Bentzon AK, Lundgren JD, Podlekareva D, Kirk O, Panteleev A, et al. Healthcare delivery for HIV–positive people with tuberculosis in Europe. HIV Medicine. 2021; 22 (4): 283–293. DOI: 10.1111/hiv.13016

21. Chang SA. Tuberculous and Infectious Pericarditis. Cardiology clinics. 2017; 35 (4): 615–622. DOI: 10.1016/j. ccl.2017.07.013

22. Méndez–Samperio P. Diagnosis of Tuberculosis in HIV Co–infected Individuals: Current Status, Challenges and Opportunities for the Future. Scandinavian journal of immunology. 2017; 86 (2): 76–82. DOI:10.1111/sji.12567

23. Golden MP, Vikram HR. Extrapulmonary tuberculosis: an overview. American family physician, 2005; 72 (9): 1761–1768.

24. Echeverri D, Matta L. Pericarditis tuberculosa. Biomedica. 2014; 34 (4): 528–534. DOI: 10.1590/S0120– 41572014000400005

25. Fowler NO. Tuberculous pericarditis. JAMA. 1991; 266 (1): 99–103.

26. Pasipanodya JG, Mubanga M, Ntsekhe M, Pandie S, Magazi BT, et al. Tuberculous Pericarditis is Multibacillary and Bacterial Burden Drives High Mortality. EBioMedicine. 2015; 2 (11): 1634–1639. DOI: 10.1016/j. ebiom.2015.09.034

27. Peel AA. Tuberculous pericarditis. Br Heart J. 1948; 10 (3): 195–207.

28. Das KM, Mansoori TA, Alattar YH, et al. Tuberculosis of the Heart: A Diagnostic Challenge. Tomography. 2022; 8 (4): 1649–1665. DOI:10.3390/tomography8040137

29. Borodulina E, Kudlay D, Vlasova B, Kuznetsova A. Potential use of in vitro tests in the diagnosis of tuberculosis (literature review). Medical Alliance. 2021; 9 (2): 15–21.

30. Бородулина Е.А., Кудлай Д.А., Кузнецова А.Н. [и др.] Использование технологической платформы ELISPOT в диагностике туберкулезной инфекции у пациентов с ВИЧ–инфекцией // Иммунология. – 2021. –Т. 42, No 4. – С.395–402. [Borodulina EА, Kudlay DA, Kuznetsova AN, et al. Ispol’zovanie tekhnologicheskoj platformy ELISPOT v diagnostike tuberkuleznoj infekcii u pacientov s VICh– infekciej [Use of the ELISPOT technology platform in the diagnosis of tuberculosis infection in patients with HIV infection]. Immunologiya [Immunology]. 2021; 42(4): 395–402. (In Russ)]. DOI: 10.33029/0206–4952–2021– 42–4–395–402

31. Syed FF, Mayosi BM. A modern approach to tuberculous pericarditis. Progress in cardiovascular diseases. 2007; 50(3): 218–236. DOI: 10.1016/j.pcad.2007.03.002

32. Бородулина Е.А., Шубина А.Т., Герасимов А.Н. [и др.]. Технологии GX для быстрой диагностики туберкулеза в учреждениях общей лечебной сети // Вестник современной клинической медицины. – 2022. – Т. 15, вып. 1. – С.7–16. [Borodulina EА, Shubina AT, Gerasimov AN, et al. Tekhnologii GX dlya bystroj diagnostiki tuberkuleza v uchrezhdeniyah obshchej lechebnoj seti [GX technologies for rapid diagnosis of tuberculosis in general medical institutions]. Vestnik sovremennoy klinicheskoy meditsiny [The Bulletin of Contemporary Clinical Medicine]. 2022; 15 (1): 7–16. (In Russ)]. DOI: 10.20969/VSKM.2022.15(1).7–16

33. Yu G, Zhong F, Shen Y, Zheng H. Diagnostic accuracy of the Xpert MTB/RIF assay for tuberculous pericarditis: A systematic review and meta–analysis. PloS one. 2021; 16 (9): e0257220. DOI: 10.1371/journal. pone.0257220

34. Wang S, Wang J, Liu J, et al. A case report and review of literature: Tuberculous pericarditis with pericardial effusion as the only clinical manifestation. Front Cardiovasc Med. 2022; 9: 1020672. DOI: 10.3389/ fcvm.2022.1020672

35. Testempassi E, Kubota K, Morooka M, et al. Constrictive tuberculous pericarditis diagnosed using 18F–fluoro-deoxyglucose positron emission tomography: a report
of two cases. AnnNucl Med. 2010; 24 (5): 421–425. DOI:10.1007/s12149–010–0365–y

36. Isiguzo G, Du Bruyn E, Howlett P, Ntsekhe M. Diagnosis and Management of Tuberculous Pericarditis: What Is New? Current cardiology reports. 2020; 22 (1): 2. DOI: 10.1007/s11886–020–1254–1

37. López–López JP, Posada–Martínez EL, Saldarriaga C, et al. Tuberculosis and the Heart. Neglected Tropical Diseases, Other Infectious Diseases Affecting the Heart (the NET-Heart Project). J Am Heart Assoc. 2021; 10 (7): e019435. DOI: 10.1161/JAHA.120.019435

38. Moussa C, Rouis, H, Debbiche S, et al. A life–threatening pericardial tamponade revealing disseminated tuberculosis: A challenging medical care. Heliyon. 2023; 9 (4): e15174. DOI: 10.1016/j.heliyon.2023.e15174

39. Hayashi H, Kawamata H, Machida M, Kumazaki T. 1998; 71 (846): 680–682. DOI:10.1259/bjr.71.846.9849395

 

 

UDC 616.127-005.4:616.15-018.5-091.818

DOI: 10.20969/VSKM.2024.17(2).98-103

REFERENCES

 

1. Аксенов А.И., Полунина О.С. Особенности ремоделирования миокарда у больных с постинфарктным кардиосклерозом и дилатационной кардиомиопатией ишемического генеза // Вестник Дагестанской государственной медицинской академии. – 2018. – Т. 1, вып. 26 – С.12–16. [Aksenov AI, Polunina OS. Osobennosti remodelirovaniya miokarda u bolnykh s postinfarktnym kardiosklerozom i dilatatsionnoy kardiomiopatiyey ishemicheskogo geneza [Features of myocardial remodeling in patients with post–infarction cardiosclerosis and dilated cardiomyopathy of ischemic origin]. Vestnik Dagestanskoy gosudarstvennoy meditsinskoy akademii [Bulletin of the Dagestan State Medical Academy]. 2018; 1(26): 12–16. (In Russ.)].

2. Zhang G, Dong D, Wan X, Zhang Y. Cardiomyocyte death in sepsis: Mechanisms and regulation (Review). Mol Med Rep. 2022; 26 (2): 257. DOI: 10.3892/mmr.2022.12773

3. Teringova E, Tousek P. Apoptosis in ischemic heart disease. J Transl Med. 2017; 15: 87. DOI: 10.1186/ s12967–017–1191–y

4. Sheng SY, Li JM, Hu XY, Wang Y. Regulated cell death pathways in cardiomyopathy. Acta Pharmacol Sin. 2023; 44 (8): 1521–1535. DOI: 10.1038/s41401–023–01068–9

5. Obeng E. Apoptosis (programmed cell death) and its signals – A review. Braz J Biol. 2021; 81 (4):1133–1143. DOI: 10.1590/1519–6984.228437

6. Huang X, Wang J. miR–1 Mediated AMPK Pathway on Cardiomyocyte Apoptosis in Hypertensive Rats. Cell Mol Biol (Noisy–le–grand). 2022; 68 (7): 135–140. DOI: 10.14715/cmb/2022.68.7.22

7. Xu X, Lai Y, Hua ZC. Apoptosis and apoptotic body: disease message and therapeutic target potentials. Biosci Rep. 2019; 39 (1): BSR20180992. DOI: 10.1042/ BSR20180992

8. Dong Y, Chen H, Gao J, Liu Y, Li J, Wang J. Molecular machinery and interplay of apoptosis and autophagy in coronary heart disease. J Mol Cell Cardiol. 2019; 136: 27–41. DOI: 10.1016/j.yjmcc.2019.09.001

9. Yang FY, Zhang L, Zheng Y, Dong H. Dexmedetomidine attenuates ischemia and reperfusion–induced cardiomyocyte injury through p53 and forkhead box O3a (FOXO3a)/p53–upregulated modulator of apoptosis (PUMA) signaling signaling. Bioengineered. 2022; 13 (1): 1377–1387. DOI: 10.1080/21655979.2021.2017611

10. Климентова Э.А., Сучков И.А., Егоров А.А., Калинин Р.Е. Маркеры апоптоза и пролиферации клеток при воспалительно–фибропролиферативных заболеваниях сосудистой стенки (обзор) // Современные технологии медицины. – 2020. – Т. 12, вып. 4. – С.119–128. [Klimentova EA, Suchkov IA, Egorov AA, Kalinin RE. Markers of apoptosis and cell proliferation in inflammatory– fibroproliferative diseases of the vascular wall (review)] Sovremenniye tekhnologii mediciny [Modern technologies in medicine]. 2020; 12 (4): 119–128. (In Russ.)].

11. Chen ZS, Yu MM, Wang K, et al. Omega–3 polyunsaturated fatty acids inhibit cardiomyocyte apoptosis and attenuate sepsis–induced cardiomyopathy. Nutrition. 2023; 106: 111886. DOI: 10.1016/j.nut.2022.111886

12. Закирова А.Н., Зарудий Ф.С., Гарифуллин Б.Н. Роль карведилола в предотвращении апоптоза кардиомиоцитов в остром периоде инфаркта миокарда // Медицинский вестник Башкортостана. – 2008. – Т. 3, вып. 1 – С.57–60. [Zakirova AN, Zarudij FS, Garifullin BN. Rol’ karvedilola v predotvrashchenii apoptoza kardiomiocitov v ostrom periode infarkta miokarda [Apoptosis prevention in acute myocardial infarction by carvedilol]. Medicinskij vestnik Bashkortostana [Medical Herald of Bashkortostan]. 2008; 3 (1): 57–60. (In Russ.)].

13. Lu X, Yang B, Qi R, Xie Q, Li T, et al. Targeting WWP1 ameliorates cardiac ischemic injury by suppressing KLF15–ubiquitination mediated myocardial inflammation. Theranostics. 2023; 13 (1): 417–437. DOI: 10.7150/ thno.77694

14. Кротова Ю.Н., Каркищенко В.Н., Хлопонин Д.П. Роль апоптоза в патологии миокарда // Биомедицина. – 2005. – Т. 1, вып. 1. – С.17–24. [Krotova YuN, Karkishchenko VN, Hloponin DP. Rol’ apoptoza v patologii miokarda [The role of apoptosis in myocardial pathology]. Biomedicina [Biomedicine]. 2005; 1 (1): 17–24. (In Russ.)].

15. Song Y, Ren X, Gao F, et al. LINC01588 regulates WWP2–mediated cardiomyocyte injury by interacting with HNRNPL. Environ Toxicol. 2022; 37 (7): 1629–1641. DOI: 10.1002/tox.23512

16. Sun T, Dong C, Xiong S. Cardiomyocyte–derived HMGB1 takes a protective role in CVB3–induced viral myocarditis via inhibiting cardiac apoptosis. Immunol Cell Biol. 2023; 101 (8): 735–745. DOI: 10.1111/imcb.12660

17. Shi H, Yu Y, Liu X, et al. Inhibition of calpain reduces cell apoptosis by suppressing mitochondrial fission in acute viral myocarditis. Cell Biol Toxicol. 2022; 38 (3): 487–504. DOI: 10.1007/s10565–021–09634–9

18. Yang Y, Li W, You B, Zhou C. Advances in cell death mechanisms involved in viral myocarditis. Front Cardiovasc Med. 2022; 9: 968752. DOI: 10.3389/ fcvm.2022.968752

19. Yu K, Zhou L, Wang Y, et al. Mechanisms and Therapeutic Strategies of Viral Myocarditis Targeting Autophagy. Front Pharmacol. 2022; 13: 843103. DOI: 10.3389/ fphar.2022.843103

20. Глухов А.И., Грызунова Г.К., Усай Л.И., [и др.]. Роль апоптоза в патогенезе некоторых критических состояний // Общая реаниматология. – 2019. – Т. 15, вып. 2 – С.79–98. [Gluhov AI, Gryzunova GK, Usaj LI, et al. Rol’ apoptoza v patogeneze nekotoryh kriticheskih sostoyanij [The role of apoptosis in the pathogenesis of some critical states]. Obshchaya reanimatologiya [General reanimatology]. 2019; 15 (2): 79–98. (In Russ.)]. DOI: 10.15360/1813–9779–2019–2–79–98

21. Xia B, Ding J, Li Q, et al. Loganin protects against myocardial ischemia–reperfusion injury by modulating oxidative stress and cellular apoptosis via activation of JAK2/STAT3 signaling. Int J Cardiol. 2023; 131426. DOI: 10.1016/j.ijcard.2023.131426

22. Jghef M, Boukholda K, Chtourou Y, et al. Punicalagin attenuates myocardial oxidative damage, inflammation, and apoptosis in isoproterenol–induced myocardial infarction in rats: Biochemical, immunohistochemical, and in silico molecular docking studies. Chem Biol Interact. 2023; 110745. DOI: 10.1016/j.cbi.2023.110745

23. Ergene S, Hemsinli D, Karakisi SO, et al. Resveratrol Attenuates Degeneration and Apoptosis of Cardiomyocytes Induced by Aortic Clamping. Braz J Cardiovasc Surg. 2023; 38 (6): e20230224. DOI: 10.21470/1678– 9741–2023–0224

24. Li J, Wang H, Chen L, et al. Ischemia–reperfusion injury in human AC16 cardiomyocytes is modulated by AXIN1 depending on c–Myc regulation. Ann Med Surg (Lond). 2023; 85 (10): 4844–4850. DOI: 10.1097/ MS9.0000000000001139

25. Лукьянова М.Е., Ермола Ю.А. Современные представления о роли апоптоза в гибели кардиомиоцитов при ишемической болезни сердца // Научно–методический электронный журнал «Концепт». – 2017. – Т. 42. – С.179–184. [Luk’yanova ME, Ermola YuA. Sovremennye predstavleniya o roli apoptoza v gibeli kardiomiocitov pri ishemicheskoj bolezni serdca [Modern views about the role of apoptosis in the death of cardiomyocytes in coronary heart disease]. Nauchno–metodicheskij elektronnyj zhurnal «Koncept» [Scientific and methodological electronic journal “Concept”]. 2017; 42: 179–184. (In Russ.)].

26. Fang Z, Lee H, Liu J, et al. Complement C3 Reduces Apoptosis via Interaction with the Intrinsic Apoptotic Pathway. Cells. 2023; 12 (18): 2282. DOI: 10.3390/ cells12182282

27. Наумов А.В., Прокофьева Т.В., Полунина О.С. [и др.]. Клинико–диагностическое значение маркеров апоптоза при инфаркте миокарда на фоне хронической обструктивной болезни лёгких // Медицинский вестник Юга России. – 2021. – Т. 12, вып. 4. – С.46–53. [Naumov AV, Prokof’eva TV, Polunina OS, et al. Kliniko– diagnosticheskoe znachenie markerov apoptoza pri infarkte miokarda na fone hronicheskoj obstruktivnoj bolezni lyogkih [Clinical and diagnostic significance of apoptosis markers in myocardial infarction in the setting of chronic obstructive pulmonary disease]. Medicinskij vestnik Yuga Rossii [Medical Herald of the South of Russia]. 2021; 12(4): 46–53. (In Russ.)]. DOI:10.21886/2219–8075– 2021–12–4–46–53

28. Xing Y, Gao Z, Bai Y, et al. Golgi protein 73 promotes LPS–induced cardiac dysfunction via mediating myocardial apoptosis and autophagy. J Cardiovasc Pharmacol. 2023. DOI: 10.1097/FJC.0000000000001487

29. Kok CY, MacLean LM, Rao R, Tsurusaki S, Kizana E. Promoter Optimization Circumvents Bcl–2 Transgene– Mediated Suppression of Lentiviral Vector Production. Biomolecules. 2023; 13 (9): 1397. DOI: 10.3390/ biom13091397

30. Zhang Y, Zhan B, Hu Y, Chen S, Zhang Q. Sevoflurane inhibits the apoptosis of hypoxia/reoxygenation–induced cardiomyocytes via regulating miR–27a–3p–mediated autophagy. J Pharm Pharmacol. 2021; 73 (11):1470–1479. DOI: 10.1093/jpp/rgab111

31. Tong M, Zablocki D, Sadoshima J. The role of Drp1 in mitophagy and cell death in the heart. J Mol Cell Cardiol. 2020; 142: 138–145. DOI: 10.1016/j.yjmcc.2020.04.015

32. Jiang X, Cai S, Jin Y, Wu F, He J, et al. Irisin Attenuates Oxidative Stress, Mitochondrial Dysfunction, and Apoptosis in the H9C2 Cellular Model of Septic Cardiomyopathy through Augmenting Fundc1–Dependent Mitophagy. Oxid Med Cell Longev. 2021; 2021: 2989974. DOI: 10.1155/2021/2989974

33. Chan GH–H, Chan E, Kwok CT–K, Leung GP–H, Lee SM–Y and Seto S–W. The role of p53 in the alternation of vascular functions. Front. Pharmacol. 2022; 13: 981152. DOI: 10.3389/fphar.2022.981152

34. Ren D, Li F, Gao A, Cao Q, Liu Y, Zhang J. Hypoxia–induced apoptosis of cardiomyocytes is restricted by ginkgolide B–downregulated microRNA–29. Cell Cycle. 2020; 19(10): 1067–1076. DOI: 10.1080/15384101.2020.1731651

35. YangH,HeX,WangC,ZhangL,YuJ,WangK. Knockdown of TUG 1 suppresses hypoxia–induced apoptosis of cardiomyocytes by up–regulating miR–133a. Arch Biochem Biophys. 2020; 681: 108262. DOI: 10.1016/j. abb.2020.108262

36. Chai Q, Miao J, Liu M, Zhang Z, Meng Z, Wu W. Knock-down of SGLT1 prevents the apoptosis of cardiomyocytes induced by glucose fluctuation via relieving oxidative stress and mitochondrial dysfunction. Biochem Cell Biol. 2021; 99 (3): 356–363. DOI: 10.1139/bcb–2020–0491

37. Zhou F, Feng T, Lu X, Wang H, Chen Y, et al. Interleukin 35 protects cardiomyocytes following ischemia/reperfusion–
induced apoptosis via activation of mitochondrial STAT3. Acta Biochim Biophys Sin (Shanghai). 2021; 53 (4): 410–418. DOI: 10.1093/abbs/gmab007

38. Bai B, Zeng G, Chen R, Ai Y, Qiang H. Upregulation of iASPP ameliorates hypoxia/reoxygenation–induced apoptosis and oxidative stress in cardiomyocytes by upregulating Nrf2 signaling. J Biochem Mol Toxicol. 2021; 35 (3): e22686. DOI: 10.1002/jbt.22686

39. Han M, Chen XC, Sun MH, Gai MT, Yang YN, et al. Overexpression of IκBα in cardiomyocytes alleviates hydrogen peroxide–induced apoptosis and autophagy by inhibiting NF–κB activation. Lipids Health Dis. 2020; 19 (1): 150. DOI: 10.1186/s12944–020–01327–2

40. Huang P, Yang D, Yu L, Shi Y. Downregulation of lncRNA ZFAS1 protects H9c2 cardiomyocytes from ischemia/ reperfusion–induced apoptosis via the miR–590–3p/ NF–κB signaling pathway. Mol Med Rep. 2020; 22 (3): 2300–2306. DOI: 10.3892/mmr.2020.11340

41. Li Q, Yang J, Zhang J, Liu XW, Yang CJ, et al. Inhibition of microRNA–327 ameliorates ischemia/reperfusion injury– induced cardiomyocytes apoptosis through targeting apoptosis repressor with caspase recruitment domain. J Cell Physiol. 2020; 235 (4): 3753–3767. DOI: 10.1002/ jcp.29270

42. Liu C, Lu D, You J, Lu Y, Sun J, et al. Efficacy of water fraction from Dioscorea cirrhosa on oxidative stress and apoptosis in H9c2 cardiomyocytes induced by H2O2. J Tradit Chin Med. 2021; 41 (1): 51–58. DOI: 10.19852/j. cnki.jtcm.2021.01.007

43. Wen Z, Mai Z, Zhu X, Wu T, Chen Y, et al. Mesenchymal stem cell–derived exosomes ameliorate cardiomyocyte apoptosis in hypoxic conditions through microRNA144 by targeting the PTEN/AKT pathway. Stem Cell Res Ther. 2020; 11 (1): 36. DOI: 10.1186/s13287–020–1563–8

44. Wu H, Zhu H, Zhuang Y, Zhang J, Ding X, et al. LncRNA ACART protects cardiomyocytes from apoptosis by activating PPAR–γ/Bcl–2 pathway. J Cell Mol Med. 2020; 24 (1): 737–746. DOI: 10.1111/jcmm.14781

45. Zhang B, Mao S, Liu X, Li S, Zhou H, et al. MiR–125b inhibits cardiomyocyte apoptosis by targeting BAK1 in heart failure. Mol Med. 202; 27 (1): 72. DOI: 10.1186/ s10020–021–00328–w

46. Wang Y, Jiang Y, Sun X, Shen X, Wang H, et al. Downregulation of miR–200a protects cardiomyocyte against apoptosis. Biomed Pharmacother. 2020; 123: 109303. DOI: 10.1016/j.biopha.2019.109303

47. Wei L, Zhou Q, Tian H, Su Y, Fu GH, Sun T. Integrin β3 promotes cardiomyocyte proliferation and attenuates hypoxia–induced apoptosis via regulating the PTEN/Akt/ mTOR and ERK1/2 pathways. Int J Biol Sci. 2020; 16 (4): 644–654. DOI: 10.7150/ijbs.39414

48. Bennett MR. Apoptosis in the cardiovascular system. Heart. 2002; 87 (5): 480–487. DOI: 10.1136/heart.87.5.480 49. Zhou L, He M, Li X, Lin E, Wang Y, et al. Molecular Mechanism of Aluminum–Induced Oxidative Damage and Apoptosis in Rat Cardiomyocytes. Biol Trace Elem Res. 2022; 200 (1): 308–317. DOI: 10.1007/s12011–
021–02646–w

50. Chen L, Li S, Zhu J, You A, Huang X, et al. Mangiferin
prevents myocardial infarction–induced apoptosis and heart failure in mice by activating the Sirt1/FoxO3a pathway. J Cell Mol Med. 2021; 25 (6): 2944–2955. DOI: 10.1111/jcmm.16329

 

UDC: 616.33–008.6

DOI: 10.20969/VSKM.2024.17(2).104-111

REFERENCES

1. Салухов В.В., Ковалевская Е.А., Сардинов Р.Т. Проблема выявления и коррекции дефицитов микро- и макроэлементов после бариатрических операций // Consilium Medicum. – 2022. – Т. 24, No 4. – С. 261–265. [Salukhov VV, Kovalevskaya EA, Sardinov RT. Problema vyyavleniya i korrekcii deficitov mikro– i makroelementov posle bariatricheskih operacij [The problem of detecting and correcting deficiencies of micro- and macronutrients after bariatric surgery]. Consilium Medicum [Consilium Medicum]. 2022; 24 (4): 261–265. (In Russ.)].

2. Peterli R, Wolnerhanssen BK, Peters T, et al. Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux– en–Y Gastric Bypass on Weight Loss in Patients With Morbid Obesity. JAMA. 2018; 319 (3): 255–265.

3. Takahashi EA, Takahashi N, Reisenauer CJ, et al. Body composition changes after left gastric artery embolization in overweight and obese Individuals. Abdominal Radiology. 2019; 44 (7): 2627–2631.

4. Егшатян Л.В., Кушханашхова Д.А., Ермилова Е.С., Аскерханов Р.Г. Микробиота кишечника у пациентов с ожирением и после бариатрических операций // Эндокринная хирургия. – 2019. – Т.13, No 1. – С.5–16. [Egshatyan LV, Kushkhanashkhova DA, Ermilova ES, Askerkhanov RG. Mikrobiota kishechnika u pacientov s ozhireniem i posle bariatricheskih operacij [Intestinal microbiota in obese patients and after bariatric surgery]. Endokrinnaya khirurgiya [Endocrine surgery]. 2019; 13 (1): 5–16. (In Russ.)].

5. Schouten R, Wiryasaputra DC, van Dielen F, et al. Long-Term Results of Bariatric Restrictive Procedures: A Prospective Study. Obesity Surgery. 2010; 20 (12): 1617–1626.

6. Малыхина А.И. Нерешенные вопросы витаминно-минеральной поддержки пациентов, перенесших бариатрические операции // Ожирение и метаболизм. – 2019. – Т. 16, No 4. – С.31–36. [Malykhina AI. Nereshennye voprosy vitaminno–mineralnoj podderzhki pacientov, perenesshih bariatricheskie operacii [Unresolved issues of vitamin and mineral support for patients who underwent bariatric surgery]. Ozhirenie i metabolizm [Obesity and metabolism]. 2019; 16 (4): 31–36. (In Russ.)].

7. Богдан В.Г., Варикаш Д.В., Дорох Н.Н. Эффективность гастрошунтирующих операций у пациентов с морбидным ожирением с различными типами нарушения пищевого поведения // Военная медицина. – 2017. – No 2. – С.34–40. [Bogdan VG, Varikash DV, Dorokh NN. Effektivnost gastroshuntiruyushih operacij u pacientov s morbidnym ozhireniem s razlichnymi tipami narusheniya pishevogo povedeniya [The effectiveness of gastric bypass surgery in patients with morbid obesity with various types of eating disorders] Voennaya medicina [Military medicine]. 2017; 2: 34–40. (In Russ.)].

8. Moura D, Oliveira J, De Moura EG, et al. Effectiveness of intragastric balloon for obesity: A systematic review and metaanalysis based on randomized control trials. Surg Obes Relat Dis. 2016; 12 (2): 420–429.

9. Омаров Т.И.О., Маилова А.А.К. Оценка эффективности рукавной резекции желUDCа в лечении пациентов с ожирением // Казанский медицинский журнал. – 2017. – Т. 98, No 1. – С.14–17. [Omarov TIO, Mailova AAK. Ocenka effektivnosti rukavnoj rezekcii zheludka v lechenii pacientov s ozhireniem [Evaluation of the effectiveness of sleeve gastric resection in the treatment of obese patients]. Kazanskij medicinskij zhurnal [Kazan Medical Journal]. 2017; 98 (1): 14–17. (In Russ.)].

10. Coulman KD, Blazeby JM. Health–related Quality of Life in Bariatric and Metabolic Surgery. Current Obesity Reports. 2020; 9 (3): 307–314.

11. Buzgova R, Buzga M, Holeczy P, Zonca P. Evaluation of Quality of Life, Clinical Parameters, and Psychological Distress after Bariatric Surgery: Comparison of the Laparoscopic Sleeve Gastrectomy and Laparoscopic Greater Curvature Plication. Bariatric Surgical Practice and Patient Care. 2016; 11 (4): 169–176.

12. Gupta S, Lodha R, Kabra Gupta SK, Asthma S. GERD and Obesity: Triangle of Inflammation. Indian Journal of Pediatrics. 2018; 85 (10): 887–892.

13. Аскерханов Г.Р., Садыки М.Н., Аскерханов Р.Г. Качество жизни пациентов с ожирением после продольной резекции желUDCа // Вестник ДГМА. – 2019. – Т. 3, No 32. – С.29–37. [Askerkhanov GR, Sadyki MN, Askerkhanov RG. Kachestvo zhizni pacientov s ozhireniem posle prodolnoj rezekcii zheludka [Quality of life of obese patients after longitudinal gastric resection]. Vestnik DGMA [Bulletin of the DGMA]. 2019; 3 (32): 29–37. (In Russ.)].

14. Чехонина Ю.Г., Гаппарова К.М., Лапик И.А., Аскерханов Р.Г. Оценка фактического питания и витаминно–минеральной обеспеченности у пациентов, перенесших бариатрические операции // Вопросы диетологии. – 2021. – Т.11, No 3. – С.13–17. [Chekhonina YG, Gapparova KM, Lapik IA, Askerkhanov RG. Ocenka fakticheskogo pitaniya i vitaminno–mineralnoj obespechennosti u pacientov, perenesshih bariatricheskie operacii [Assessment of actual nutrition and vitamin and mineral security in patients who underwent bariatric surgery] Voprosy dietologii [Questions of dietetics]. 2021; 11 (3): 13–17. (In Russ.)].

15. Бойцов С.А., Погосова Н.В., Бубнова М.Г. [и др.]. Кардиоваскулярная профилактика 2017. Российские национальные рекомендации // Российский кардиологический журнал. – 2018. – Т. 23, No 6. – С.7–122. [Boitsov SA, Pogosova NV, Bubnova MG, et al. Kardiovaskulyarnaya profilaktika 2017: Rossijskie nacionalnye rekomendacii [Cardiovascular prevention 2017: Russian national recommendations]. Rossijskij kardiologicheskij zhurnal [Russian Journal of Cardiology]. 2018; 23 (6): 7–122. (In Russ.)].

16. Дедов И.И., Мельниченко Г.А., Шестакова М.В. [и др.]. Лечение морбидного ожирения у взрослых // Ожирение и метаболизм. – 2018. – Т. 15, No 1. – С.53–70. [Dedov II, Melnichenko GA, Shestakova MV, et al. Lechenie morbidnogo ozhireniya u vzroslyh [Treatment of morbid obesity in adults]. Ozhirenie i metabolizm [Obesity and metabolism]. 2018; 15 (1): 53–70. (In Russ.)].

17. Орлов Ю.П., Говорова Н.В., Лукач В.Н., [и др.]. Метаболизм железа в условиях инфекции // Вестник интенсивной терапии им. А.И. Салтанова. – 2020. – Т.1. – С.90–99. [Orlov YP, Govorova NV, Lukach VN, Baitugaeva GA, Klementyev AV, Kakulya EN. Metabolizm zheleza v usloviyah infekcii [Iron metabolism in conditions of infection]. Vestnik intensivnoj terapii imeni AI Saltanova [Bulletin of intensive therapy named after AI Saltanov]. 2020; 1: 90–99. (In Russ.)].

18. Меньшикова Л.В., Бабанская Е.Б. Половозрастная эпидемиология ожирения // Ожирение и метаболизм. – 2018. – Т. 15, No 2. – С.17–22. [Menshikova LV, Babanskaya EB. Polovozrastnaya epidemiologiya ozhireniya [Gender and age epidemiology of obesity]. Ozhirenie i metabolizm [Obesity and metabolism]. 2018; 15 (2): 17–22. (In Russ.)].

19. Мирчук К.К., Василевский Д.И., Анисимова К.А., Давлетбаева Л.И. Метаболические эффекты бариатрических операций // Педиатр. – 2019. – Т. 10, No 2. – С.99–109. [Mirchuk KK, Vasilevsky DI, Anisimova KA, Davletbaeva LI. Metabolicheskie effekty bariatricheskih operacij [Metabolic effects of bariatric operations]. Pediatr [Pediatrician]. 2019; 10 (2): 99–109. (In Russ.)].

20. Волынкина А.П., Золоедов В.И., Наумова Н.В. [и др.]. Развитие железодефицитной и В12–дефицитной анемии у пациентов после бариатрических операций // Многопрофильный стационар. – 2022. – Т. 9, No 2. – С.56–60. [Volinkina AP, Zolotoyedov VI, Naumova NV, et al. Razvitie zhelezodeficitnoj i V12–deficitnoj anemii u pacientov posle bariatricheskih operacij [The development of iron deficiency and B12 deficiency anemia in patients after bariatric surgery]. Mnogoprofilnyj stacionar [Multidisciplinary hospital]. 2022; 9 (2): 56–60. (In Russ.)].

21. Фишман М.Б., Куприн П.Е., Турмаханов С.Т. Наиболее часто применяемая в бариатрической практике операция продольной резекции желUDCа. Отдаленные
результаты // Эндоскопическая хирургия. – 2019. – Т. 25, No 1. – С.17–22. [Fishman MB, Kuprin PE, Turmakhanov ST. Naibolee chasto primenyaemaya v bariatricheskoj praktike operaciya prodolnoj rezekcii zheludka; Otdalennye rezultaty [The most commonly used operation in bariatric practice is longitudinal gastric resection; Long–term results]. Endoskopicheskaya hirurgiya [Endoscopic surgery]. 2019; 25 (1): 17–22. (In Russ.)].

22. Aljiffry M, Habib R, Kotbi E, et al. Acute Pancreatitis: A Complication of Intragastric Balloon. Surg Laparosc Endosc Percutan Tech. 2017; 27 (6): 456–459.

23. Ball W, Raza S, Loy J, et al. Effectiveness of Intra–Gastric Balloon as a Bridge to Definitive Surgery in the Super Obese. Obesity Surgery. 2019; 29 (6): 1932–1936.

24. Weiss CR, Abiola GO, Fischman AM, et al. Bariatric Embolization of Arteries for the Treatment of Obesity (BEAT Obesity) Trial: Results at 1 Year. Radiology. 2019; 291 (3): 792–800.

25. Фирсова Л.Д., Бодунова Н.А., Полякова В.В., Аскерханов Р.Г. Бариатрический пациент на приеме у гастроэнтеролога до и после операции // Эффективная фармакотерапия. – 2021. – Т. 17, No 16. – С.102–107. [Firsova LD, Bodunova NA, Polyakova VV, Askerkhanov RG. Bariatricheskiy patsiyent na priyeme u gastroenterologa do i posle operatsii [A bariatric patient at a gastroenterologist’s appointment before and after surgery]. Effektivnaya farmakoterapiya [Effective pharmacotherapy]. 2021; 17 (16): 102–107. (In Russ.)].

26. Dedov II, Melnichenko GA, Troshina EA, et al. Body Weight Reduction Associated with the Sibutramine Treatment: Overall Results of the PRIMAVERA Primary Health Care Trial. Obesity Facts. 2018; 11 (4): 335–343.

27. Dolezalova–Kormanova K, Buchwald JN, Skochova D, et al. Five–Year Outcomes: Laparoscopic Greater Curvature Plication for Treatment of Morbid Obesity. Obesity Surgery. 2017; 27 (11): 2818–2828.

28. Гуреева И.Л., Волкова А.Р., Семикова Г.В. [и др.] Удовлетворенность качеством жизни и эмоциональное состояние у пациентов с морбидным ожирением до и после бариатрических операций // Вестник межнационального центра исследования качества жизни. – 2021. – No 37–38. – С.21–30. [Gureeva IL, Volkova AR, Semikova GV, et al. Udovletvorennost kachestvom zhizni i emocionalnoe sostoyanie u pacientov s morbidnym ozhireniem do i posle bariatricheskih operacij [Satisfaction with the quality of life and emotional state in patients with morbid obesity before and after bariatric surgery]. Vestnik mezhnacionalnogo centra issledovaniya kachestva zhizni [Bulletin of the International Center for Quality of Life Research]. 2021; 37–38: 21–30. (In Russ.)].

29. Muir LA, Neeley CK, Meyer KA, et al. Adipose tissue fibrosis, hypertrophy, and hyperplasia: Correlations with diabetes in human obesity . Obesity (Silver Spring). 2016; 24 (3): 597–605.

30. Кручинин Е.В., Маликова А.Ж., Орлова И.С., Саидова П.А. Показатели углеводного обмена у пациентов с ожирением после выполненной бариатрической операции // Университетская медицина Урала. – 2019. – Т. 5, No 1(16). – С.92–94. [Kruchinin EV, Malikova AZh, Orlova IS, Saidova PA. Pokazateli uglevodnogo obmena u pacientov s ozhireniem posle vypolnennoj bariatricheskoj operacii [Indicators of carbohydrate metabolism in obese patients after bariatric surgery]. Universitetskaya medicina Urala [University medicine of the Urals]. 2019; 5, 1 (16): 92–94. (In Russ.)].

31. Molina GA, Palacios Gordon MF, Jerez Ortiz JR, et al. Bowel obstruction due to the migration of the deflated intragastric balloon, a rare and potentially lethal complication. Journal of Surgical Case Reports. 2019; 4: 1–4.

32. Musella M, Susa A, Manno E, et al. Complications Following the Mini/One Anastomosis Gastric Bypass (MGB/OAGB): a Multi–institutional Survey on 2678 Patients with a Mid–term (5 Years) Follow–up. Obesity Surgery. 2017; 27 (11): 2956–2967.

33. Pishe M–E, Tardif I, Auclair A, Poirier P. Effects of bariatric surgery on lipid–lipoprotein profile. Metabolism. 2021; 115: 1–41.

34. Смурова Е.Л. Особенности пищевого поведения у пациентов с морбидным ожирением до и после бариатрической операции // Forcipe. – 2022. – Т. 5, No S3. – С.378–379. [Smurova EL. Osobennosti pishevogo povedeniya u pacientov s morbidnym ozhireniem do i posle bariatricheskoj operacii [Peculiarities of eating behavior in patients with morbid obesity before and after bariatric surgery]. Forcipe [Forcipe]. 2022; 5 (S3): 378–379. (In Russ.)].

35. Hachem A, Brennan L. Quality of life outcomes of bariatric surgery: a systematic review. Obesity Surgery. 2016; 26 (2): 395409.

36. Hassn A, Luhmann A, Rahmani S, Morris–Stiff G. Medium–Term Results of Combined Laparoscopic Sleeve Gastrectomy and Modified Jejuno–Ileal Bypass in Bariatric Surgery. Obesity Surgery. 2016; 26 (10): 2316–2323.

37. Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2017; 13 (3): 479–504.

38. Lee YH, Park J, Min S, et al. Impact of Visceral Obesity on the Risk of Incident Metabolic Syndrome in Metabolically Healthy Normal Weight and Overweight Groups: A Longitudinal Cohort Study in Korea. Korean Journal of Family Medicine. 2020; 41 (4): 229–236.

39. Lukacs A, Horvath E, Mate Z, et al. Abdominal obesity increases metabolic risk factors in non–obese adults: a Hungarian cross–sectional study. BMC Public Health. 2019; 19 (1): 1–8.

40. Аутлев К.М., Кручинин Е.В., Алиев Ф.Ш. [и др.] Динамика развития артериальной гипертензии у пациентов с морбидным ожирением, перенесших бариатрическую операцию // Медицинская наука и образование Урала. – 2020. – Т. 21, No 1(101). – С.75–78. [Аutlev KM, Kruchinin EV, Aliev FS, et al. Dinamika razvitiya arterialnoj gipertenzii u pacientov s morbidnym ozhireniem, perenesshih bariatricheskuyu operaciyu [Dynamics of arterial hypertension in patients with morbid obesity who underwent bariatric surgery]. Medicinskaya nauka i obrazovanie Urala [Medical science and education of the Urals]. 2020; 21, 1 (101): 75–78. (In Russ.)].

41. Talebpour M, Sadid D, Talebpour A, et al. Comparison of Short–Term Effectiveness and Postoperative Com-
plications: Laparoscopic Gastric Plication vs Laparoscopic Sleeve Gastrectomy. Obesity Surgery. 2017; 28 (4): 996–1001.

42. Tell GS, Kolotkin RL, et al. Changes in quality of life 5 years after sleeve gastrectomy: a prospective cohort study. BMJ Open. 2019; 9 (9): 1–11.

43. Trang J, Lee SS, Miller A, et al. Incidence of nausea and vomiting after intragastric balloon placement in bariatric patients – A systematic review and meta–analysis. International Journal of Surgery. 2018; 57: 22–29.

44. Fried M, Yumuk V, Oppert JM, et al. Interdisciplinary European guidelines on metabolic and bariatric surgery. Obesity surgery. 2014; 24 (1): 42–55.

45. Неймарк М.И., Жилин С.В. Особенности инфузионной терапии при бариатрических операциях // Вестник анестезиологии и реаниматологии. – 2022. – Т. 19, No 6. – С.48–54. [Neymark MI, Zhilin SV. Osobennosti infuzionnoj terapii pri bariatricheskih operaciyah [Features of infusion therapy in bariatric surgery]. Vestnik anesteziologii i reanimatologii [Bulletin of Anesthesiology and Intensive Care]. 2022; 19 (6):48–54. (In Russ.)].

46. Poelemeijer YQM, van der Knaap ETW, Marang–van de Mheen PJ. Measuring quality of life in bariatric surgery: a multicentre study. Surgical Endoscopy. 2020; 34 (12): 5522–5532.

47. Рекун Е.Г., Шубина С.Н., Хрущ И.А., Дорох Н.Н. Важность оценки психического статуса пациентов перед проведением бариатрических операций (с описанием клинического случая) // Военная медицина. – 2022. – No 1 (62). – С.108–110. [Rekun EG, Shubina SN, Khrushchev IA, Dorokhov NN. Vazhnost ocenki psihicheskogo statusa pacientov pered provedeniem bariatricheskih operacij (s opisaniem klinicheskogo sluchaya) [The importance of assessing the mental status of patients before bariatric surgery (with a description of the clinical case)]. Voennaya medicina [Military medicine]. 2022; 1 (62): 108–110. (In Russ.)].

48. Climent E, Benaiges D, Goday A, Villatoro M. Morbid obesity and dyslipidaemia: The impact of bariatric surgery. Clin. Investig. Arterioscler. 2020; 32 (2): 79–86.

49. Nguyen NT, Varela JE. Bariatric surgery for obesity and metabolic disorders: state of the art. Nature Reviews Gastroenterology & Hepatology. 2016; 14 (3): 160–169.

50. Williams B, Mancia G, Spiering W, et al. ESC/ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension. Eur Heart J. 2018; 39 (33): 3021–3104.

 

UDC: 616.831.71–007–073.756.8:616.714.35–089.87

DOI: 10.20969/VSKM.2024.17(2).112-117

REFERENCES

 

1. Кузбеков А.Р., Магжанов Р.В., Сафин Ш.М. Современные представления о мальформации Киари // Медицинский вестник Башкортостана. – 2011. – Т.6, No6. – С.118–125. [Kuzbekov AR, Magzhanov RV, Safin SHM. Sovremennye predstavleniya o mal’formacii Kiari [Modern ideas about Chiari malformation]. Medicinskij vestnik Bashkortostana [Medical Bulletin of Bashkortostan]. 2011; 6 (6): 118–125. (In Russ.)].

2. Doyon D, Sigal R, Poylegot G, et al. MRI of spinal cord congenital malformations. J Neuroradiol. 1987; 14 (3):185–201.

3. Файзутдинова А.Т., Богданов Э.И. Клинико–радиологическое обоснование выделения подтипов первичной мальформации Киари 1–го типа // Журнал неврологии и психиатрии им. С.С. Корсакова. – 2020. – Vol.120, No8. – С.64–69. [Fajzutdinova AT, Bogdanov EI. Kliniko– radiologicheskoe obosnovanie vydeleniya podtipov pervichnoj mal’formacii Kiari 1–go tipa [Clinical and radiological rationale for identifying subtypes of primary Chiari malformation type 1]. Zhurnal nevrologii i psihiatrii [Journal of Neurology and Psychiatry]. 2020; 120 (8): 64–69. (In Russ.)]. DOI: 10.17116/jnevro202012008164

4. Morgenstern PF, Tosi U, Uribe–Cardenas R, at al. Ventrolateral Tonsillar Position Defines Novel Chiari 0.5 Classification. World Neurosurg. 2020; 136: 444–453. DOI: 10.1016/j.wneu.2020.01.147

5. Tubbs RS, Turgut M. Defining the Chiari Malformations: Past and Newer Classifications; In The Chiari Malformations, 2nd ed. Cham, Switzerland: Springer Nature Publishing. 2020; 21–40.

6. Крупина Н.Е. Сведения о семейных случаях сирингомиелии, базилярной импрессии и мальформации Киари // Неврологический вестник. – 2001. – No1–2. – С.70–75. [Krupina NE. Svedeniya o semejnyh sluchayah siringomielii, bazilyarnoj impressii i mal’formacii Kiari [Information on familial cases of syringomyelia, basilar impression and Chiari malformation]. Nevrologicheskij vestnik [Neurological Bulletin]. 2001; 1–2: 70–75. (In Russ.)].

7. McLone DG, Knepper PA. The cause of Chiari II malformation: a unified theory. Pediatr Neurosci. 1989; 15 (1): 1–12.

8. Mancarella C, Delfini R, Landi A. Chiari Malformations. Acta Neurochir Suppl. 2019; 89–95. DOI:10.1007/978– 3–319–62515–7_13

9. Луцик А.А., Раткин И.К., Никитин М.Н. Краниовертебральные повреждения и заболевания. – Новосибирск: «Издатель», 1998. – С.337–412. [Lucik AA, Ratkin IK, Nikitin MN. Kraniovertebral’nye povrezhdeniya i zabolevaniya [Craniovertebral injuries and diseases]. Novosibirsk: «Izdatel’» [Novosibirsk: “Publisher”]. 1998; 337–412. (In Russ.)].

10. Speer MC, Enterline DS, Mehltretter L, et al. Chiari type I malformation with or without syringomyelia: prevalence and genetics. J Genet Couns. 2014; 12 (4): 297–311. DOI: 10.1023/A:1023948921381

11. Wu YW, Chin CT, Chan KM, et al. Pediatric Chiari I malformations: do clinical and radiologic features correlate? Neurology. 1999; 53 (6): 1271–1276. DOI: 10.1212/wnl.53.6.1271

12. Genitori L, Peretta P, Nurisso C, at al. Chiari type I anomalies in children and adolescents: minimally invasive management in a series of 53 cases. Childs Nerv Syst. 2000; 16 (10): 707–718. DOI: 10.1007/ s003810000338

13. Dyste GN, Menezes AH, VanGilder JC, et al. Symptomatic Chiari malformations. An analysis of presentation, management, and long–term outcome. J Neurosurg. 1989; 171 (2): 159–168. DOI: 10.3171/jns.1989.71.2.0159

14. Milhorat TH, Chou MW, Trinidad EM, et al. Chiari I malformation redefined: clinical and radiographic findings for 364 symptomatic patients. Neurosurgery. 1999; 44 (5): 1005–1017. DOI: 10.1097/00006123–199905000–00042

15. Azahraa HF, Qaisi I, Joudeh N, et al. The newer classifications of the Chiari malformations with clarifications: An anatomical review. Clinical Anatomy. 2018; 31 (3): 314–322. DOI: 10.1002/ca.23051

16. Aitken LA, Lindan CE, Sidney S, et al. Chiari type I malformation in a pediatric population. Pediatr Neurol. 2009; 40 (6): 449–454. DOI: 10.1016/j.pediatrneurol.2009.01.003

17. Alexandrou M, Politi M, Papanagiotou P. Chiari–Malformation. Der Radiologe. 2018; 58 (7): 626–628. DOI: 10.1007/ s00117–018–0399–z

18. Freyschmidt J. Borderlands of Normal and Early Pathological Findings in Skeletal Radiography, ed 5. New York: Thieme. 2003; 236 p.

19. McClugage SG, Oakes WJ. The Chiari I malformation. J Neurosurg Pediatr. 2019; 24 (3): 217–226. DOI: 10.3171/2019.5.PEDS18382

20. Frič R, Eide PK. Chiari type 1–a malformation or a syndrome? A critical review. Acta Neurochir (Wien). 2020; 162 (7): 1513–1525. DOI: 10.1007/s00701–019–04100–2

21. Богданов Э.И. Клиническая значимость подпороговых эктопий миндалин мозжечка в большое затылочное отверстие и мальформация Киари нулевого типа // Вопросы нейрохирургии имени Н.Н. Бурденко. – 2022. – Т. 86, No 3. – С.91–97. [Bogdanov EI. Klinicheskaya znachimost’ podporogovyh ektopij mindalin mozzhechka v bol’shoe zatylochnoe otverstie i mal’formaciya Kiari nulevogo tipa [Clinical significance of subthreshold ectopia of the cerebellar tonsils into the foramen magnum and Chiari malformation type zero]. Voprosy nejrohirurgii imeni NN Burdenko [Issues of neurosurgery named after NN Burdenko]. 2022; 86 (3): 91–97. (In Russ.)]. DOI: 10.17116/ neiro20228603192

22. Bogdanov EI, Faizutdinova AT, Mendelevich EG, et al. Epidemiology of symptomatic Chiari Malformation in Tatarstan: regional and ethnic differences in prevalence. Neurosurgery. 2019; 84 (5): 1090–1097. DOI:10.1093/ neuros/nyy175

23. Bogdanov EI, Faizutdinova AT, Heiss JD. The Small Posterior Cranial Fossa Syndrome and Chiari Malformation Type 0. J Clin Med. 2022; 17 (18): 5472. DOI: 10.3390/ jcm11185472

24. Iskandar BJ, Hedlund GL, Grabb PA, et al. The resolution of syringohydromyelia without hindbrain herniation after posterior fossa decompression. J Neurosurg. 1998; 89: 212–216. DOI: 10.3171/jns.1998.89.2.0212

25. Tubbs RS, Elton S, Grabb P, et al. Analysis of the posterior fossa in children with the Chiari 0 malformation. Neurosurgery. 2001; 48: 1050–1055. DOI: 10.1097/00006123–200105000–00016

26. Kyoshima K, Kuroyanagi T, Oya F, et al. Syringomyelia without hindbrain herniation: tight cisterna magna. Report of four cases and a review of the literature. J Neurosurg. 2002; 96: 239–249. DOI: 10.3171/spi.2002.96.2.0239

27. Haddad FA, Qaisi I, Joudeh N, et al. Then ewer classifications of the Chiari malformations with clarifications: An anatomical review. Clin Anat. 2017; 31: 314–322. DOI: 10.1002/ca.23051

28. Bolognese PA, Brodbelt A, Bloom AB, et al. Chiari I Malformation: Opinions on Diagnostic Trends and Controversies from a Panel of 63 International Experts. World Neurosurg. 2019; 130: 9–16. DOI: 10.1016/j. wneu.2019.05.098

29. Rindler RS, Chern JJ. Newer Subsets: Chiari 1.5 and Chiari 0 Malformations; In The Chiari Malformations, 2nd ed. Springer. 2020; 41–46.

30. Thompson DNP. Chiari I—A ‘not so’ congenital malformation? Child’s Nerv Syst. 2019; 35: 1653–1664. DOI: 10.1007/s00381–019–04296–9

31. Богданов Э.И. Дислокации миндалин мозжечка в большое затылочное отверстие и спектр мальформаций Киари 1–го типа // Журнал неврологии и психиатрии им. С.С. Корсакова. – 2022. – Т.122, No4. – С.7–15. [Bogdanov EI. Dislokacii mindalin mozzhechka v bol’shoe zatylochnoe otverstie i spektr mal’formacij Kiari 1–go tipa [Dislocations of the cerebellar tonsils into the foramen magnum and the spectrum of Chiari malformations type 1]. Zhurnal nevrologii i psihiatrii imeni SS Korsakova [Journal of Neurology and Psychiatry named after SS Korsakov]. 2022; 122 (4): 7–15. (In Russ.)]. DOI: 10.17116/ jnevro20221220417

32. Meadows J, Kraut M, Guarnieri M, et al. Asymptomatic Chiari Type I malformations identified on magnetic resonance imaging. J Neurosurg. 2000; 92: 920–926. DOI: 10.3171/jns.2000.92.6.0920

33. Fischbein R, Saling JR, Marty P, et al. Patient–reported Chiari malformation type I symptoms and diagnostic experiences: a report from the national Conquer Chiari Patient Registry database. Neurol Sci. 2015; 36 (9): 1617–1624. DOI: 10.1007/s10072–015–2219–9

34. Fernandez AA, Guerrero AI, Martinez MI, et al. Malformations of the craniocervical junction (Chiari type I and syringomylia: classification, diagnosis and treatment). BMC Musculoskelet Disord. 2009; 10 (1): 1–11. DOI: 10.1186/1471–2474–10–S1–S1

35. Speer MC, Enterline DS, Mehltretter L, al. Chiari type i malformation with or without syringomyelia: prevalence and genetics. J Genet Couns. 2014; 12 (4): 297–311. DOI: 10.1023/A:1023948921381

36. Genitori L, Peretta P, Nurisso C, at al. Chiari type I anomalies in children and adolescents: minimally invasive management in a series of 53 cases. Childs Nerv Syst. 2000; 16 (10): 707–718. DOI: 10.1007/s003810000338

37. Schijman E. History, anatomic forms, and pathogenesis of Chiari I malformations. Childs Nerv Syst. 2004; 20 (5): 323–328. DOI: 10.1007/s00381–003–0878–y

38. Zhang ZQ, Chen YQ, Chen YA, et al. Chiari I malformation associated with syringomyelia: a retrospective study of 316 surgically treated patients. Spinal Cord. 2007; 46 (5): 358–363. DOI: 10.1038/sj.sc.3102141

39. Богданов Э.И., Ярмухаметова М.Р. Аномалия Арнольда–Киари: патогенез, клинические варианты, классификация, диагностика и лечение // Вертеброневрология. – 1998. – No2–3. – С.68–73. [Bogdanov EI, Yarmuhametova MR. Anomaliya Arnol’da–Kiari: patogenez, klinicheskie varianty, klassifikaciya, diagnostika i lechenie [Anomaly Arnold–Chiari: pathogenesis, clinical variant, classification, diagnosis and treatment]. Vertebronevrologiya [Vertebroneurology]. 1998; 2–3: 68–73. (In Russ.)].

40. Mueller DM. Prospective analysis of presenting symptoms among 265 patients with radiographic evidence of Chiari malformation type I with or without syringomyelia. J Neuroradiol. 1998; 14 (3): 185–186. DOI: 10.1111/j.1745– 7599.2004.tb00384.x

41. Langridge B, Phillips E, Choi D. Chiari Malformation Type 1: A Systematic Review of Natural History and Conservative Management. World Neurosurgery. 2017; 104: 213–219. DOI: 10.1007/s10072–021–05347–3

42. Novegno F. Clinical diagnosis–part II: what is attributed to Chiari I. Childs Nerv Syst. 2019; 35: 1681–1693. DOI: 10.1007/s00381–019–04192–2

43. McClugage SG, Oakes WJ. The Chiari I malformation. J Neurosurg Pediatr. 2019; 24: 217–226. DOI: 10.3171/2019.5.PEDS18382

44. Zainon I, Mohamad I. Vocal Cord Palsy in Arnold Chiari Type 1 Malformation with 415 Syringomyelia: A Case Report. International. Medical Journal. 2012; 19 (1): 69–70.

45. Decq P, Guérinel C, Sol J, et al. Chiari I malformation: a 436 rare cause of noncommunicating hydrocephalus treated by third ventriculostomy. J Neurosurg. 2001; 95 (5): 783–790. DOI: 10.3171/jns.2001.95.5.0783

46. Менделевич Е.Г., Михайлов М.К., Богданов Э.И. Сирингомиелия и мальформация Арнольда—Киари (клинико–нейровизуальные аспекты). – Казань: Медицина, 2002. – 238 с. [Mendelevich EG, Mikhailov MK, Bogdanov EI. Syringomyelia and Arnold–Chiari malformation (clinical–neurovisual aspects) [Syringomyelia and Arnold– Chiari malformation (clinical–neurovisual aspects)]. Kazan: Medicina [Kazan: Medicine]. 2002; 238 p.].

47. Ellenbogen R, Bauer D. Association between fibromyalgia, chronic fatigue, and the Chiari I malformation. In: Tubbs RS, Oakes WJ (eds) The Chiari malformations. Springer Science Business Media, New York. 2013; 265–271.

48. Wan MJ, Nomura H, Tator CH. Conversion to symptomatic Chiari I malformation after minor head or neck trauma.
Neurosurgery. 2008; 63: 748–753. DOI: 10.1227/01.
NEU.0000325498.04975.C0

49. Greenlee JDW, Donovan KA, Hasan DM, et al. Chiari
I malformation in the very young child: the spectrum of presentations and experience in 31 children under age 6 years. Pediatrics. 2002; 110: 1212–1219. DOI: 10.1542/ peds.110.6.1212

50. Elster AD, Chen MY. Chiari I malformations: clinical and radiologic reappraisal Radiology. 1992; 183 (2): 347–353. DOI: 10.1148/radiology.183.2.1561334

51. Tubbs RS, Lyerly MJ, Loukas M, et al. The pediatric Chiari I malformation: a review Childs Nerv Syst. 2007; 23 (11): 1239–1250. DOI: 10.1007/s00381–007–0428–0

52. Barkovich AJ, Wippold FJ, Sherman JL, et al. Significance of cerebellar tonsillar position on MR AJNR Am J Neuroradiol. 1986; 7 (5): 795–799.

53. Killeen A, Roguski M, Chavez A, et al. Non–operative outcomes in 377 Chiari I malformation patients Clin Neuroscience. 2015; 22 (1): 133–138. DOI: 10.1016/j. jocn.2014.06.008

54. Chavez A, Roguski M, Killeen A, et al. Comparison of operative and 374 non–operative outcomes based on surgical selection criteria for patients with Chiari I 375 malformations J Clin Neuroscience. 2014; 21 (12): 220. DOI: 10.1016/j.jocn.2014.06.009

55. Ramón C, Gonzáles–Mandly A, Pascual J. What Differences Exist in the Appropriate 393 Treatment of Congenital Versus Acquired Adult Chiari Type I Malformation? Curr Pain Headache Rep. 2011; 15 (3): 157–163. DOI: 10.1007/s11916–011–0182–6

56. Shalom NJ, Zarchi NB, Michowiz S, et al. Conservative management for pediatric patients with Chiari 1 anomaly: A retrospective study. Clinical Neurology and Neurosurgery. 2019; 189: 11–23. DOI: 10.1016/j. clineuro.2019.105615

 

UDC 616.12-008.46-07

DOI: 10.20969/VSKM.2024.17(2).118-123

REFERENCES

 

1. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017; 390 (10100): 1211-1259. DOI: 10.1016/ S0140-6736(17)32154-2

2. Castiglione V, Aimo A, Vergaro G, et al. Biomarkers for the diagnosis and management of heart failure. Heart Fail Rev. 2022; 27 (2): 625-643. DOI: 10.1007/s10741-021-10105-w

3. de Oliveira FL, Gatto M, Bassi N, et al. Galectin-3 in autoimmunity and autoimmune diseases. Exp Biol Med (Maywood). 2015; 240 (8): 1019-1028. DOI: 10.1177/1535370215593826

4. Khadeja Bi A, Santhosh V, Sigamani K. Levels of Galectin-3 in Chronic Heart Failure: A Case-Control Study. Cureus. 2022; 14 (8): e28310. DOI: 10.7759/cureus.28310

5. Suthahar N, Meijers WC, Silljé HHW, et al. Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update. Theranostics. 2018; 8 (3): 593-609. DOI: 10.7150/thno.22196

6. Zaborska B, Sikora-Frąc M, Smarż K, et al. The Role of Galectin-3 in Heart Failure-The Diagnostic, Prognostic and Therapeutic Potential-Where Do We Stand? Int J Mol Sci. 2023; 24 (17): 13111. DOI: 10.3390/ijms241713111

7. Hara A, Niwa M, Noguchi K, et al. Galectin-3 as a Next-Generation Biomarker for Detecting Early Stage of Various Diseases. Biomolecules. 2020; 10 (3): 389. DOI: 10.3390/ biom10030389

8. Desmedt V, Desmedt S, Delanghe JR, Speeckaert R, Speeckaert MM. Galectin-3 in Renal Pathology: More Than Just an Innocent Bystander. Am J Nephrol. 2016; 43 (5): 305-317. DOI:10.1159/000446376

9. Blanda V, Bracale UM, Di Taranto MD, Fortunato G. Galectin-3 in Cardiovascular Diseases. Int J Mol Sci. 2020; 21 (23): 9232. DOI: 10.3390/ijms21239232

10. Venkatraman A, Hardas S, Patel N, et al. Galectin-3: an emerging biomarker in stroke and cerebrovascular diseases. Eur J Neurol. 2018; 25 (2): 238-246. DOI:10.1111/ ene.13496

11. de Boer RA, Yu L, van Veldhuisen DJ. Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep. 2010; 7 (1): 1-8. DOI:10.1007/s11897-010-0004-x

12. Sygitowicz G, Maciejak-Jastrzębska A, Sitkiewicz D. The Diagnostic and Therapeutic Potential of Galectin-3 in Cardiovascular Diseases. Biomolecules. 2022; 12 (1): 46. DOI: 10.3390/biom12010046

13. Yang RY, Rabinovich GA, Liu FT. Galectins: structure, function and therapeutic potential. Expert Rev Mol Med. 2008; 10: e17. DOI:10.1017/S1462399408000719

14. Sanchez-Mas J, Lax A, Asensio-Lopez MC, et al. Galectin-3 expression in cardiac remodeling after myocardial
infarction. Int J Cardiol. 2014; 172 (1): e98-e101. DOI: 10.1016/j.ijcard.2013.12.129

15. Sharma UC, Pokharel S, van Brakel TJ, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004; 110 (19): 3121-3128. DOI: 10.1161/01.CIR.0000147181.65298.4D

16. Gonzalez GE, Cassaglia P, Noli Truant S, et al. Galectin-3 is essential for early wound healing and ventricular remodeling after myocardial infarction in mice. Int J Cardiol. 2014; 176: 1423-1425. DOI: 10.1016/j.ijcard.2014.08.011

17. Shaukat S, Nadeem A, Mazloom F, Rameez R. Correlation of Serum Galectin-3 Levels with Ejection Fractions in Healthy Subjects and Heart Failure Patients. Pak J Physiol. 2022; 18 (2): 28-30. Available at: https://pjp.pps.org.pk/ index.php/PJP/article/view/1427

18.Mosleh W, Chaudhari MR, Sonkawade S, et al. The Therapeutic Potential of Blocking Galectin-3 Expression in Acute Myocardial Infarction and Mitigating Inflammation of Infarct Region: A Clinical Outcome-Based Translational Study. Biomarker Insights. 2018; 13. DOI: 10.1177/1177271918771969

19. Chen K, Jiang RJ, Wang CQ, et al. Predictive value of plasma galectin-3 in patients with chronic heart failure. Eur Rev Med Pharmacol Sci. 2013; 17 (8): 1005-1011. PMID: 23661512

20. Tang WH, Shrestha K, Shao Z, et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol. 2011; 108 (3): 385-390. DOI: 10.1016/j.amjcard.2011.03.056

21. Подзолков В.И., Драгомирецкая Н.А., Казадаева А.В. [и др.]. Взаимосвязи активности нейрогормональных систем и параметров внутрисердечной гемодинамики у больных хронической сердечной недостаточностью: фокус на галектин-3 // Российский кардиологический журнал. – 2022. – Т.27, вып. 4. – С.73-78. [Podzolkov VI, Dragomiretsksya NA, Kazadaeva AV, at all. Vzaimosvyazi aktivnosti nejrogormonal’nyh sistem i parametrov vnutriserdechnoj gemodinamiki u bol’nyh hronicheskoj serdechnoj nedostatochnost’yu: fokus na galektin-3 [Relationships between the activity of neurohormonal systems and intracardiac hemodynamics in patients with heart failure: focus on galectin-3]. Rossijskij kardiologicheskij zhurnal [Russian Journal of Cardiology]. 2022; 2 (4): 73-78. (In Russ.)]. DOI: 10.15829/1560-4071-2022-4957

22. Дуболазова Ю.В., Драпкина О.М. Применение галектина-3 и NT-proBNP в качестве биомаркеров декомпенсированной сердечной недостаточности // Российский кардиологический журнал. – 2017. – No 1. – C.95-101. [Dubolazova YuV, Drapkina OM. Primenenie galektina-3 i NT-proBNP v kachestve biomarkerov dekompensirovannoj serdechnoj nedostatochnosti [Galectin-3 and NT-proBNP as biomarkers of heart failure decompensation]. Rossijskij kardiologicheskij zhurnal [Russian Journal of Cardiology]. 2017; 1: 95-101. (In Russ.)]. DOI: 10.15829/1560-4071-2017-1-95-101

23. Jaarsma T, Van Der Wal MH, Hogenhuis J, et al. Design and methodology of the COACH study: a multicenter randomised Coordinating study evaluating Outcomes of Advising and Counselling in Heart failure. Eur J Heart Fail. 2004; 6 (2): 227-233. DOI: 10.1016/j. ejheart.2003.09.010

24. de Boer RA, Lok DJ, Jaarsma T, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011; 43 (1): 60-68. DOI:10.3109/07853890.2010.538080

25. Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure With Preserved Ejection Fraction. Circulation. 2017; 136 (1): 6-19. DOI: 10.1161/CIRCULATIONAHA.116.026807

26. Sundström J, Bruze G, Ottosson J, et al. Weight Loss and Heart Failure: A Nationwide Study of Gastric Bypass Surgery Versus Intensive Lifestyle Treatment. Circulation. 2017; 135 (17): 1577-1585. DOI: 10.1161/ CIRCULATIONAHA.116.025629

27. Meijers WC, de Boer RA, van Veldhuisen DJ, et al. Biomarkers and low risk in heart failure. Data from COACH and TRIUMPH. Eur J Heart Fail. 2015; 17 (12): 1271-1282. DOI: 10.1002/ejhf.407

28. Testa M, Rosso GL, Ferreri C, Feola M. The Predictive Value of Plasma Brain Natriuretic Peptide and Galectin-3 in Elderly Patients Admitted for Heart Failure. Diseases. 2018; 6 (4): 88. DOI: 10.3390/diseases6040088

29. Altun Özgür, Dikker O, Akarsu M, et al. The relationship of serum galectin-3 levels with obesity and insulin resistance. J Surg Med. 2019; 3 (8): 564-567. DOI: 10.28982/ josam.602984

30. Kiwaki K, Novak CM, Hsu DK, Liu FT, Levine JA. Galectin-3 stimulates preadipocyte proliferation and is up-regulated in growing adipose tissue. Obesity (Silver Spring). 2007; 15 (1): 32–39. DOI:10.1038/oby.2007.526

31. Takada N, Takasugi M, Nonaka Y, et al. Galectin-3 promotes the adipogenic differentiation of PDGFRα+ cells and ectopic fat formation in regenerating muscle. Development. 2022; 149 (3): dev199443. DOI: 10.1242/ dev.199443

32. Baek JH, Kim SJ, Kang HG, et al. Galectin-3 activates PPARγ and supports white adipose tissue formation and high-fat diet-induced obesity. Endocrinology. 2015; 156 (1): 147-156. DOI: 10.1210/en.2014-1374

33. Pejnovic N. Galectin-3 In Obesity And Type 2 Diabetes. Ser J Exp Clin Res. 2015; 16 (4): 273-280. DOI: 10.1515/ SJECR-2015-0057

34. Nurjannah N, Nurahmi N, Kurniawan LB. Correlation Analysis of Galectin-3 Serum Level in Obesity with and without Obesity. Indonesian J. Clin. Pathol. Med. Lab. 2023; 29 (3): 216-219. DOI: 10.24293/ijcpml. v29i3.2048

35. Haass M, Kitzman DW, Anand IS, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail. 2011; 4 (3): 324-331. DOI: 10.1161/CIRCHEARTFAILURE.110.959890

36. Kenchaiah S, Pocock SJ, Wang D, et al. Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 2007; 116 (6): 627-636. DOI: 10.1161/ CIRCULATIONAHA.106.679779

37. Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002; 347 (5): 305-313. DOI: 10.1056/NEJMoa020245

38. Lv J, Li Y, Shi S, et al. Skeletal muscle mitochondrial remodeling in heart failure: An update on mechanisms and therapeutic opportunities. Biomed Pharmacother. 2022; 155: 113833. DOI: 10.1016/j.biopha.2022.113833 39. Zhang X, Xie X, Dou Q, et al. Association of sarcopenic obesity with the risk of all-cause mortality among adults over a broad range of different settings: a updated meta-analysis. BMC Geriatr. 2019; 19 (1): 183. DOI: 10.1186/s12877-019-1195-y

40. Fonseca GWPD, Dos Santos MR, de Souza FR, et al. Discriminating sarcopenia in overweight/obese male patients with heart failure: the influence of body mass index. ESC Heart Fail. 2020; 7 (1): 84-91. DOI: 10.1002/ ehf2.12545

41. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol. 2009; 53 (21): 1925-1932. DOI: 10.1016/j.jacc.2008.12.068

42. Sato R, Vatic M, da Fonseca GWP, von Haehling S. Sarcopenia and Frailty in Heart Failure: Is There a Biomarker Signature? Curr Heart Fail Rep. 2022; 19 (6): 400-411. DOI: 10.1007/s11897-022-00575-w

43. Komici K, Gnemmi I, Bencivenga L, et al. Impact of Galectin-3 Circulating Levels on Frailty in Elderly Patients with Systolic Heart Failure. J Clin Med. 2020; 9 (7): 2229. DOI: 10.3390/jcm9072229

44. Kong HH, Won CW, Kim W. Effect of sarcopenic obesity on deterioration of physical function in the elderly. Arch Gerontol Geriatr. 2020; 89: 104065. DOI: 10.1016/j. archger.2020.104065

45. Kitzman DW, Brubaker P, Morgan T, et al. Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. JAMA. 2016; 315 (1): 36-46. DOI: 10.1001/jama.2015.17346

46. Ohori K, Yano T, Katano S, et al. High percent body fat mass predicts lower risk of cardiac events in patients with heart failure: an explanation of the obesity paradox. BMC Geriatr. 2021; 21 (1): 16. DOI: 10.1186/s12877-020-01950-9

47. Bahat G, Tufan A, Kilic C, et al. Prevalence of sarcopenia and its components in community-dwelling outpatient older adults and their relation with functionality. Aging Male. 2020; 23 (5): 424-430. DOI: 10.1080/13685538.2018.1511976

48. Delmonico MJ, Harris TB, Visser M, et al. Longitudinal study of muscle strength, quality, and adipose tissue infiltration. Am J Clin Nutr. 2009; 90 (6): 1579-1585. DOI: 10.3945/ajcn.2009.28047

49. Konishi M, Kagiyama N, Kamiya K, et al. Impact of sarcopenia on prognosis in patients with heart failure with reduced and preserved ejection fraction. Eur J Prev Cardiol. 2021; 28 (9): 1022-1029. DOI: 10.1093/eurjpc/zwaa117

50. Saito H, Matsue Y, Kamiya K, et al. Sarcopenic obesity is associated with impaired physical function and mortality in older patients with heart failure: insight from FRAGILE-HF. BMC Geriatr. 2022; 22(1): 556. DOI: 10.1186/s12877-022-03168-3

 

CLINICAL CASE

UDC:616.612-056.7-053.3:616.631.11:616.152.18

DOI: 10.20969/VSKM.2024.17(2).124-129

DERBENEVA LARISA I., ORCID ID: 0000-0002-5416-9042; Cand. sc. med., Associate Professor at the Department of Hospital Pediatrics and Neonatology, Astrakhan State Medical University, 121 Bakinskaya str., 414000 Astrakhan, Russia. Tel.: +79086144917. E-mail: derbenewal@yandex.ru

GERNER MARINA G., ORCID ID:0009-0005-5236-8952; Nephrologist at the Department of Urology, Regional Children’s Clinical Hospital named after N.N. Silishcheva, 6 Medikov str., 414011 Astrakhan, Russia. Tel.: +79033785547. E-mail: cindirella.gerner@yandex.ru

RABEEVA ALINA G., ORCID ID: 0009-0008-1265-1632; Nephrologist at the Department of Urology, Regional Children’s Clinical Hospital named after N.N. Silishcheva, 6 Medikov str., 414011 Astrakhan, Russia. Tel.: +79378220322. E-mail: zagoruiko.al@ya.ru

TORISHNEVA ZHANNA E., ORCID ID: 0009-0002-8576-4941; Nephrologist at the Advisory Department, Regional Children’s Clinical Hospital named after N.N. Silishcheva, 6 Medikov str., 414011 Astrakhan, Russia. Tel.: +79170862547. E-mail: torishnevazhanna@yandex

Abstract. Introduction. Phosphate diabetes is a representative of a group of diseases known as tubulopathies. It is more often of a hereditary nature. The disease manifests at an early age with symptoms similar to alimentary rickets, which creates problems for diagnosing and prescribing an adequate therapy. In this case, the current situation leads to the development of bone deformities and disability, delayed physical development, and the need for surgical treatment, which reduces the quality of life of the patients for a long time. Aim: To consider two clinical cases of phosphate diabetes with typical symptoms, demonstrate the diagnosing challenges, and analyze the treatment effects. Materials and Methods. Two clinical cases of phosphate diabetes are presented. The first patient: 16 years old, observed from the age of 2, and takes vitamin D and inorganic phosphates from the diagnosis date. The geneticist found the autosomal dominant of the pathology. The girl underwent two surgeries for her leg deformity. The second patient, 10 years old, was diagnosed at the age of 4 years. DNA diagnostics detected a mutation in the COL9A3 gene. They refused the complete DNA exome sequencing. From the diagnosis date, the patient is treated with the active vitamin D metabolite and inorganic phosphates. Results and Discussion. Clinician-observed: Patient 1 had leg deformities, painful legs, and disharmonious physical development caused by her growth retardation. Blood concentrations of calcium and phosphorus are within normal, there is hypocalciuria typical of phosphate diabetes in the urine, while phosphates are within normal. The patient’s kidney function is not impaired. Clinician-observed: Patient 2 is physically retarded, there are varus foot deformities and pes planovalgus feet. Kidney function is not impaired, the level of alkaline phosphatase is increased, the total blood calcium levels are decreased with phosphorus indicating normal values, and the urine phosphaturia and hypocalciuria are within normal ranges. Due to the COL9A3 mutation detected, Stickler syndrome was excluded. Orthopedic surgeon recommended surgical treatment of her leg deformities. Conclusions. The examination showed that the therapy allows keeping phosphate diabetes under control and avoiding the side effects of taking vitamin D.

Keywords: phosphate diabetes, tubulopathy, children, diagnosis, treatment, active vitamin D metabolite, inorganic phosphates

For reference: Davydova OV, Antonova AA, Derbeneva LI, Gerner MG, Rabeeva AG, Torishneva JE. Renal hereditary tubulopathies: Phosphate diabetes (two clinical cases). The Bulletin of Contemporary Clinical Medicine. 2024; 17(2): 124-129. DOI: 10.20969/VSKM.2024.17(2).124–129.

REFERENCES